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Background: Dementia is a growing challenge, and there is no curative treatment 
available. The most common cause of dementia is Alzheimer’s disease (AD), where 
treatment studies focusing on anti-amyloid treatment have thus far failed. 
Importantly, age-specific incidence of dementia has fallen in many countries, 
possibly due to life style changes and improved treatment of modifiable risk factors, 
among them vascular risk factors. However, knowledge about the effect of vascular 
risk factors on the progression of dementia is scarce. Of note, anthocyanins, found 
naturally in a number of foods, may protect against cardiovascular related cognitive 
impairment and dementia. Concerning AD, recent studies have investigated lipid 
alterations in AD pathogenesis, with the potential to complement the proteomic 
approaches as potential biomarkers of diagnosis and progression of AD.  
Aim: To increase knowledge about the role of vascular risk factors, lipid alterations 
and anthocyanin supplementation with respect to development and progression of 
cognitive impairment in a population of people with mild dementia or at increased 
risk of dementia. In paper I, the objective was to examine the potential effect of 
vascular risk factors on the progression of AD and Lewy body dementia (LBD). 
Paper II explored the plasma lipid profile in mild cognitive impairment due to AD 
and its association with cognition. Lastly, paper III explored the potential effects of 
anthocyanins on mechanisms relevant for cognitive decline in people with increased 
risk of dementia.  
Methods: Data from three different studies were analysed, including two longitudinal 
multicenter cohort studies; “Dementia study in Western Norway” (DemVest), and 
“Dementia Disease Initiation” (DDI). DemVest included newly diagnosed dementia 
patients from specialist clinics in old age psychiatry and geriatric medicine in 
Western Norway in the period of 2005-2013. DDI is a nationwide ongoing study 
including participants with cognitive impairment and normal controls from 2013 
onwards from self-referrals from advertisements in media, newspapers and news 
bulletins, and referrals from general practitioners to the local memory clinics. In both 




neuropsychological tests, clinical examination, and imaging. Cerebrospinal fluid was 
also analysed. In addition, an open-label pilot study, the Anthocyanin study, recruited 
participants with increased risk of dementia from the outpatient Memory and 
Cardiology clinics at Stavanger University Hospital in Norway during 2015 and 
2016, who received anthocyanin supplementation for 16 weeks. For comparison, 
normal controls not receiving anthocyanin supplementation were recruited. 
Results: In paper I, smoking was the only vascular risk factor significantly associated 
with a more rapid cognitive decline, in patients with AD as measured by Clinical 
Dementia Rating Scale Sum of Boxes (CDR-SB). In contrast, being overweight was 
associated with a slower cognitive decline in both AD and LBD. Hypertension 
predicted slower decline in Mini-Mental Status Exam (MMSE) scores in all patients, 
and in the LBD group. Further, in the LBD group diabetes mellitus and smoking were 
found to be associated with a slower decline in CDR-SB scores, and in MMSE scores 
respectively. In paper II, a number of plasma sphingomyelin concentrations, and 
particularly SM(d43:2), were found to be lower in mild cognitive impairment (MCI) 
in cerebrospinal fluid amyloid beta positive (Aβ+) individuals compared to controls. 
SM(d43:2) was also nominally reduced in MCI Aβ+ individuals compared to in 
cerebrospinal fluid amyloid beta negative (Aβ-) participants with MCI. In addition, 
two phosphatidylinositols were negatively associated with visuospatial functioning at 
baseline. In paper III, a significant group difference was found for monocyte 
chemoattractant protein (MCP-1) and fasting glucose. In the anthocyanin group total 
cholesterol and triglycerides increased significantly, and improvements in memory 
and executive test scores were observed at study end. 
Conclusions and implications: Smoking cessation might potentially slow down the 
cognitive decline in AD. Since some other vascular risk factors were associated with 
slower decline, further studies are needed to explore how this potentially can be 
translated into benefit for people with dementia. Larger studies of longer duration are 
warranted in order to investigate the role of lipid alterations during AD pathogenesis 
and progression. Randomized controlled trials are needed to explore the potential 
effects of anthocyanins on cognitive decline and dementia risk. 
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Cognitive impairment, and particularly dementia, represents a burden for the persons 
diagnosed with dementia, their next of kin or carers, and the entire society [4-6]. With 
the increasing number of people surviving into old age, the prevalence, incidence and 
cost of dementia is expected to increase significantly [4]. In 2018 it was estimated to 
be 50 million people living with dementia worldwide, a number expected to triple by 
2050 [7]. It is estimated that around 101 000 people are living with dementia in 
Norway [8]. 
Of note, there is some evidence that the incidence of dementia is decreasing in 
industrialized countries, possibly related to improved reduction of dementia risk 
factors such as hypertension, obesity, smoking, diabetes mellitus, and cerebrovascular 
disease and increased exposure to protective influences such as level of education, a 
healthy lifestyle and balanced diet [4, 9-12]. Importantly, a delay in the onset of 
dementia has been shown to benefit even the oldest old, possibly due to fewer years 
of life with dementia [13]. 
Nutrition has been reported to be an important modifiable risk factor for cognitive 
impairment [14]. The most reported diets with relevance for age-related cognitive 
decline, Alzheimer’s disease (AD) and dementia development include the so-called 
“Mediterranean diet” [15], adherence to which has been reported to possibly 
contribute to better cognitive performance and protection against cognitive 
impairment and dementia [16, 17]. The Mediterranean diet contains flavonoids, a 
subgroup of polyphenols found in foods such as berries and fruits [15]. Further, 
polyphenols and anthocyanins, a subclass of the flavonoids, have been shown to 
possibly have a protective effect against cardiovascular related cognitive decline 
through the modification of a number of risk factors common to neurodegeneration 
due to AD, vascular dementia (VaD), and cerebrovascular disease [18]. This includes 
anti-inflammatory and antioxidative effects, improved lipid profile, decreased risk of 
diabetes mellitus type 2 and dysfunctional glucose metabolism, and improved 
endothelial and vascular function [19-24]. 
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Interestingly, midlife vascular risk factors, such as hypertension, 
hypercholesterolemia, and obesity, have been found in large observational studies not 
only to be risk factors for VaD, but also AD and dementia [25-29] However, whether 
vascular risk factors affect the progression of dementia is not clear [30].  
With respect to hypercholesterolemia, which is a risk factor for atherosclerosis, 
cardio- and cerebrovascular diseases, it is also associated with an accumulation of 
amyloid beta (Aβ) [31]. Further, cholesterol and other lipids have important structural 
and functional roles in the brain, and disruption of lipid homeostasis may contribute 
to neurodegenerative disease such as AD [32-34].  
This thesis focuses on the role of vascular risk factors, lipid alterations and 
anthocyanin supplementation with respect to development and progression of 
cognitive impairment in a population of people with mild dementia or at increased 
risk of dementia, with a focus on AD and Lewy body dementia (LBD). 
 Dementia 
The widely used International Classification of Diseases and Health Related 
Problems version 10 (ICD-10) by the World Health Organisation (WHO) defines 
dementia as a syndrome due to disease of the brain, usually of a chronic or 
progressive nature [35]. Impairment must be present in memory, and at least one 
additional cognitive domain with intact consciousness. The duration of symptoms has 
to be at least six months, and the impairment must represent a decline from the prior 
level of functioning affecting activities of daily living. 
The International Classification of Diseases 11th revision recently published requires 
two impaired cognitive domains, however neither has to include memory [36].  
Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria have also been 
used for diagnosing dementia, and in the latest version of DSM-5, Mild and Major 
Neurocognitive Disorders are introduced, the latter equated with dementia [37].  
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The most common cause of dementia is dementia due to AD, followed by VaD, and 
LBD [4]. As they share a number of clinical and pathological similarities, dementia 
with Lewy bodies (DLB) and Parkinson disease dementia (PDD) are often referred to 
as LBD [38]. Importantly, with increasing age, a combination of different 
pathologies, i.e. mixed dementia, is very common [4]. Other diseases include 
frontotemporal dementia (FTD) and the recently described limbic-predominant age-
related TDP-43 encephalopathy (LATE) [39].  
The most common neurodegenerative diseases causing dementia are AD and Lewy 
body disease. Both are pathologies of disturbed protein homeostasis involving 
misfolding of proteins, including amyloid, tau [40] and α-synuclein [41], leading to 
synaptic dysfunction and neuronal loss, and also several secondary pathologies such 
as inflammation, oxidative stress, and mitochondrial damage [42]. Of note, 
neurodegenerative conditions evolve for many years before a threshold of neuronal 
loss is reached that causes clinical signs [43, 44]. The ability to detect the earliest 
stage of these conditions is important in order to possibly intervene while neuronal 
viability is still present. 
 Mild Cognitive Impairment 
Mild cognitive impairment (MCI) usually precedes dementia but the boundary 
between the two is not always clear. Patients with MCI are a heterogeneous group 
where some develop dementia, while some remain stable, and some even improve, 
however the risk of developing dementia is higher in persons diagnosed with MCI 
than in the general population [4]. According to Winblad criteria, MCI is defined as a 
report of cognitive decline from either the patient or an informant in addition to 
impairment on objective cognitive tasks, or as decline over time on cognitive tasks or 
tests, with relatively preserved activities of daily living [45]. Of note, ICD-11 is now 
using the same terminology as DSM-5; “mild neurocognitive disorder”, described as 
a subjective experience of cognitive decline with objective impairment in one or more 
cognitive domains, but not sufficiently severe to interfere with activities of daily 
living [36].  
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After fulfilling the criteria for the dementia or MCI syndrome diagnosis, relevant 
differential diagnosis must be considered in order to ascertain the specific underlying 
disease [4]. In the clinical setting this includes history taking, general clinical 
examination, including a brief neurological examination, as well as routine blood 
tests, and neuroimaging such as magnetic resonance imaging (MRI) or a computed 
tomography (CT). Cognitive testing must be standardised and cover relevant 
cognitive domains. Biomarkers such as the volume of the hippocampal region on 
MRI, cerebrospinal fluid (CSF) AD markers of Aβ42, phosphorylated tau (p-tau) and 
total-tau (t-tau), DAT-SPECT (dopamine transporter imaging), 18F-
fluorodeoxyglucose (FDG), and amyloid positron emission tomography (PET) are 
increasingly used in clinical practice [4]. A definitive diagnosis of dementia type can 
only be made after neuropathological analysis post mortem [46, 47].  
Hence, the means used today for differentiating the underlying causes of dementias 
are costly procedures with potential unwanted side-effects. Thus, low-cost and safe 
blood-based biomarkers are of interest. Research on blood-based AD biomarkers, for 
example Aβ, tau, phosphorylated tau, and neurofilament light chain, is progressing 
and is likely to be relevant also for the differential diagnosis [48, 49]. Further, despite 
the focus that has been on proteomics, investigating lipid alterations during AD 
pathogenesis will complement the proteomic approaches channeled towards the 
development of early diagnosis of AD [32]. 
 Alzheimer’s Disease 
1.3.1 Epidemiology 
AD is the most common cause of dementia, accounting for 50-75% of all dementia 
cases [50]. A meta-analysis from 2017 concludes that the prevalence of AD for those 
above 65 years in Europe is just above 5%, the prevalence in men being 3.3 % and 
7.1% in women. The incidence is increasing with age in both sexes as [51]. 
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1.3.2 Pathology 
The two core pathological hallmarks of AD are extracellular amyloid plaques and 
intracellular neurofibrillar tangles [40]. Amyloid plaques are deposits of Aβ peptides 
generated from the transmembrane amyloid precursor protein which can either be 
cleaved by the α- and the γ-secretases, or by the β secretase and γ-secretase where the 
latter has been described as the “amyloidogenic pathway” leading to formation of Aβ 
peptides of different lengths, including Aβ42, deposited in amyloid plaques [52]. 
Morphologically different subset of Aβ deposits can be found at the centre of 
dystrophic neurites as neuritic plagues, and in blood vessels as cerebral amyloid 
angiopathy [47]. 
The degree and distribution of the core AD hallmarks have previously been described 
by Braak and Braak [53]. Neurofibrillar tangles are divided into six stages where 
stages I-II refers to neurofibrillar tangles confined to the transenthorinal area, stages 
III-IV also involving the limbic area and the more severe stages V-VI having 
neocortical involvement [53]. Regarding amyloid deposits, three stages are described 
where A is characterised as low densities of amyloid deposits in the isocortex, B by 
medium amyloid densities in almost all isocortical association areas, and in stage C 
amyloid deposits can be seen in all areas of the isocortex [53].  
The pathogenesis of AD is unknown. However, the amyloid cascade hypothesis 
proposes that deposition of Aβ causes the tau neurofibrillary tangle formation and 
secondary changes including glial activation, neuroinflammation, oxidative stress, 
autophagy and mitochondrial dysfunction, disturbance of the blood-brain barrier and 
microcirculation and synaptic dysfunction, triggering neuronal dysfunction and death 
[40, 42, 54]. 
1.3.3 Clinical features  
AD is generally characterised by an insidious onset and slow gradual decline. The 
first symptoms vary from person to person, however a typical presentation of AD is 
the amnestic syndrome, though deficits in executive functions are also common [55]. 
A more atypical presentation with relatively preserved memory involves a decline in 
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non-amnestic aspects of cognition, such as word-finding, attention, visiospatial 
symptoms, impaired reasoning or judgment [55] which occur in approximately 6-
14% of cases, and usually has an earlier onset [56]. The rate of decline varies but is 
generally irreversible, and as the disease progresses, people experience greater 
memory loss and other cognitive difficulties.  
The first clinical stage is often labelled subjective cognitive decline, where the 
individual and close family members may notice some subtle changes but cognitive 
testing and function is still within normal range [57]. The next stage is MCI where 
symptoms are somewhat more pronounced, and impairment is detected on 
neuropsychological testing [45]. Diagnostic guidelines for MCI due to AD involving 
AD biomarkers have been published by the National Institute on Aging and 
Alzheimer’s Association workgroups (NIA-AA) [58].  
The dementia stage, as described previously (section 1.1) requires a cognitive decline 
from a prior level and impairment of activities of daily living present for at least six 
months [35]. The functional impairments first apparent is often problems with 
demanding and complex tasks such as the handling of financial issues. Then, 
gradually challenges evolve with different instrumental activities of daily living, such 
as housekeeping, cooking and shopping before progression to difficulties with basic 
activities such as dressing and hygiene. In the severe stage of AD the patient cannot 
talk, walk, or eat independently. 
Of note, whereas cognitive and functional impairment typically deteriorates along the 
course of disease progression, behavioral and non-cognitive symptoms such as 
motor-, neuropsychiatric- and behavioral symptoms may occur in all phases of the 
disease [59], and are often found to be present at the time of dementia diagnosis [60]. 
Neuropsychiatric symptoms include hyperactivity (aggression, irritability, 
disinhibition, aberrant motor behavior and euphoria), psychosis (delusions, 
hallucinations and sleep disorder), affective symptoms (depression and anxiety), and 
apathy. The most common neuropsychiatric symptom in AD is apathy, followed by 
depression, aggression and anxiety [59].  
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1.3.4 Diagnosis 
The National Institute of Neurological and Communicative Disorders and Stroke and 
the Alzheimer’s disease and Related Disorders Association (NINCDS-ADRA) 
proposed the first criteria for AD in 1984, focusing on clinical symptoms [61]. The 
revised 2011 criteria included not only clinical symptoms, but combined them with 
biomarkers of AD pathology found in CSF (Aβ42, total tau and phosphorylated tau) 
enabling the diagnosis of AD prior to onset of dementia [62]. 
The NIA-AA criteria published in 2018 describe how AD may be a biological 
continuum that includes formation of amyloid plaques (A), neurofibrillary tangles (T) 
and neurodegeneration (N), giving an ATN classification system based on CSF and 
imaging biomarkers [63]. In this classification biomarkers of Aβ plaques (A) are 
cortical amyloid PET ligand binding or low CSF Aβ42, and biomarkers of fibrillar 
tau (T) are elevated CSF P-tau and cortical tau PET ligand binding specific for AD. 
Biomarkers of neurodegeneration or neuronal injury (N) are FDG PET 
hypometabolism, and atrophy on MRI not specific to AD, but CSF t-tau is also 
classified as a neurodegeneration biomarker [63]. Of importance, the authors stress 
that it is premature and inappropriate to use this research framework in general 
medical practice [63]. 
1.3.5 Treatment 
At the moment there are no disease-modifying treatments available for AD. Several 
phase III trials with anti-amyloid agents have failed [64], however with some mixed 
but slightly more promising results with phase-III aducanumab recently reported [65, 
66]. The medications available are based on neurotransmitter manipulation involving 
cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) increasing the 
acetylcholine activity, while memantine reduces the glutamatergic activity through its 
action on N-methyl D aspartate (NMDA) receptors. The use of these drugs alone or 
in combination gives, at best, a detectable, but modest response in some patients 
reducing the clinical symptoms of AD [67]. Of note, clinical guidelines mainly 
recommend non-pharmacological treatment as first line treatment, and 
pharmacological treatment when indicated should be used in combination with non-
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pharmacological interventions [4]. Non-pharmacological interventions and behavioral 
strategies such as activities matched to interest, exercise programs, cognitive training, 
music therapy and psychosocial interventions like day-care centers are recommended 
as first line treatment [4, 67]. Pharmacological treatment may be necessary if patients 
experience severe neuropsychiatric symptoms or depression. The evidence of efficacy 
of antipsychotics is scarce and the side-effects are possibly severe. Regarding 
depression a selective serotonin-reuptake inhibitor is the preferred drug of choice [4]. 
 Lewy body dementia  
Lewy body dementia (LBD) is a common term used for Parkinson disease with 
dementia (PDD) and dementia with Lewy bodies (DLB). Even though they are two 
clinical syndromes that differ in the sequence of onset of dementia and parkinsonism, 
both syndromes and underlying pathological changes become similar with disease 
progression and can be viewed as a continuum [68].  
1.4.1 Epidemiology 
Dementia with lewy bodies 
Numbers of DLB prevalence in the population vary, and a systematic reviews reports 
prevalence between 0 % - 21.9% of cases [69, 70]. Of note, DLB is reported to be 
underdiagnosed, especially in primary health care where the prevalence has been 
reported to be 4.2% while in secondary health care the prevalence was reported to be 
7.5% [69, 71].  
Parkinson’s disease with dementia 
The prevalence of PDD among all dementia cases is estimated to be 3-4%, and in the 
general population aged 65 years and over the prevalence estimate is 0.2 - 0.5% [72]. 
Further, up to 80% of patients with Parkinson’s disease progress to dementia. The 
point-prevalence estimate of PDD in patients with Parkinson’s disease is 25% with 
increasing estimates with age reaching 50% 10 years after diagnosis [68]. 
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1.4.2 Pathology 
The pathological hallmark of LBD are Lewy bodies in the cell soma of neurons and 
Lewy neurites in neuronal cell processes, mainly consisting of misfolded α-synuclein. 
DLB and PDD cannot be distinguished neuropathologically [68]. The lewy pathology 
is accompanied by neuronal loss, however whether the Lewy bodies and Lewy 
neurites are neurotoxic and associated with the neuronal loss is unknown as autopsies 
have shown severe α-synuclein pathology in some individuals who had no clinical 
symptoms of LBD [73, 74]  
Braak et al. have proposed a caudal-to-rostral spreading of Lewy body pathology in 
Parkinson’s disease (with or without dementia) divided into six stages. In stage 1 
pathology starts in the medulla oblongata and anterior olfactory nucleus, and in stage 
2 pathology spreads in the medulla ablongata and pontine structures. At stage 3 the 
disease has entered the substantia nigra and Lewy body lesions begin to form in the 
pars compacta before stage 4 were pathology involves limbic structures and temporal 
cortex. At stage 5 and 6 the neocortex are affected [75].  
1.4.3 Diagnosis 
Dementia with Lewy bodies 
DLB is not defined in the ICD-10, but is described in the DSM-5 as Major and Minor 
Neurocognitive disorder with Lewy bodies [37] and also in the ICD-11 [36]. The 
DLB consortium criteria first published in 1996, and later revised in 2005 and 2017 
by McKeith et al. are often being used [76-78]. Revisions were done in order to 
increase the sensitivity of the diagnosis.  
In all the revisions, dementia as a central clinical feature is consistent. Fluctuating 
cognition, visual hallucinations, and parkinsonism have been constant as core clinical 
feature. Rapid eye movement-sleep behavior disorder was added as a supportive 
feature to the 2005 criteria and included as a core clinical feature in the 2017 criteria 
[78]. The 2005 criteria included the supportive clinical features of repeated falls, 
syncope, transient loss of consciousness, neuroleptic sensitivity, systematised 
delusions, and hallucinations [76]. However, in the latest criteria more features are 
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listed, such as severe autonomic dysfunction, e.g. constipation, orthostatic 
hypotension, urinary incontinence; hypersomnia; hyposmia; hallucinations in other 
modalities; systematised delusions; apathy, anxiety, and depression [78]. 
Further, the 2017 criteria include reduced dopamine transporter uptake in the basal 
ganglia by PET or SPECT (dopamine transporter imaging), abnormal 
metaiodobenzylguanidine (MIBG) myocardial scintigraphy and polysomnography 
confirming rapid eye movement sleep without atonia as indicative biomarkers.  
DLB is diagnosed clinically as probable or possible, depending on symptoms and 
findings. According to the latest criteria, possible DLB can be diagnosed with one 
core clinical feature or one indicative biomarker. A probable DLB diagnosis can be 
made if there are two core clinical features or one core clinical feature and one 
indicative biomarker [78]. 
Dementia occurring before or concurrently with parkinsonism should be labeled 
DLB, while dementia which develops in patients with an established PD diagnosis 
should be labeled PDD [78].  
Parkinson’s disease with dementia 
According to the ICD-10 critera, PDD is defined as “dementia developing in the 
course of established Parkinson disease. No particular distinguishing clinical features 
have yet been demonstrated” [35].  
The International Parkinson and Movement Disorder Society provided in 2007 
clinical diagnostic criteria for probable and possible PDD [79]. In short, the criteria 
require the core features of Parkinson’s disease and dementia to be present in both 
probable and possible PDD where dementia is defined similar to the ICD-10 criteria, 
however without the specification that memory must be affected. Further, a probable 
PDD diagnosis requires that the patient has a cognitive profile with impairment of at 
least 2 domains attention, executive functions, visuo-spatial functions, and impaired 
free recall memory which usually improves with cueing. Having at least one 
behavioral feature such as apathy, daytime sleepiness, delusions or hallucinations, 
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supports the diagnosis. For a possible PDD diagnoses attention is preserved, and the 
associated features show atypical profile f.ex. having aphasia or if retrieval of 
memory is not improved when a cue or word related to the information is given. 
Further, behavioral symptoms may or may not be present. Possible PDD is also 
diagnosed if the patient has comorbidity that may explain the cognitive making the 
PDD diagnosis uncertain, or if the time interval from motor and cognitive symptoms 
is not known. 
1.4.4 Clinical features 
Dementia with Lewy bodies 
Clinically DLB is characterised by dementia, with variable combinations of the 
clinical core features of parkinsonism, rapid eye movement sleep behavior disorder, 
fluctuating cognition/alertness, and visual hallucinations [78]. It has been reported 
that DLB patients present cognitive impairment characterised by impaired attention, 
executive- and visuospatial functions rather than impaired memory function. 
However, as noted in the recently proposed criteria for prodromal DLB, the 
symptoms and core clinical features may be mild or absent in the prodromal stages 
[44].  
Prodromal DLB is a term used to describe a pre-dementia stage where the symptoms 
indicate that DLB will develop, which presents with cognitive deficits and a variable 
presentation of non-cognitive clinical features including motor symptoms, autonomic 
dysfunction, sleep disorders and neuropsychiatric disturbances [44] 
Parkinson’s disease with dementia 
Parkinson’s disease is clinically defined as a movement disorder characterised by 
motor symptoms such as bradykinesia, rigidity, resting tremor, and postural 
instability [80]. Cognitive decline, among the most common non-motor symptoms in 
PD develops gradually, however little is known about subjective cognitive decline in 
PD, and no established criteria exists for this syndrome [80].  
MCI-PDD has been defined in a similar way as AD-MCI, in the context of 
established PD [81].  
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In PDD the core symptoms of both Parkinson’s disease and dementia are present. 
Further, associated clinical features in PDD are deficits in cognitive features related 
to attention, visuospatial functions, executive functions, and memory. The core 
function and behavioral features include personality changes, excessive daytime 
sleepiness, apathy, delusions, and hallucinations [79]. Neuropsychiatric symptoms are 
frequent in PDD and the most common symptoms are reported to be depression, 
anxiety, apathy and hallucinations [82]. 
1.4.5 Treatment  
As for AD, there are no available disease modifying agents for LBD treatment. A 
newly published review on LBD treatment concludes that rivastigmine and donepezil 
are the best choices of treatment for cognitive symptoms in LBD. Memantine might 
also have some benefits, but whether memantine should be used as a monotherapy or 
be combined with cholinesterase inhibitors is not clear [83]. 
Patients with LBD often present a variety of neuropsychiatric symptoms. 
Unfortunately, the evidence base for non-pharmacological interventions in patients 
with Lewy body dementia is weak [83]. If the symptoms are distressing 
pharmacological management should be given in which case cholinesterase inhibitors 
might help. Low dosage Quetiapine is considered to be the safest choice for patients 
with LBD as it has fewer side effects, while clozapine is recommended in PDD. 
Treatment of depression in LBD is difficult as studies are less conclusive, however a 
selective serotonin-reuptake inhibitor seems to be the best choice [83]. For the 
management of motor symptoms in patients with LBD, both acute and chronic 
levodopa monotherapy are found to improve motor function, although more so in 
patients with PDD than in those with DLB [83]. Interestingly, an epileptic drug 
zonisamide have been reported to improve motor function when used in combination 
with levodopa in patients with DLB [84].  
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 Risk factors for cognitive impairment 
Cognitive impairment, including dementia, generally results from a complicated 
interplay between unmodifiable and modifiable risk factors across the lifespan [4, 9].  
1.5.1 Unmodifiable risk factors 
Increasing age is the most important risk factor for dementia and AD, with 
exponential increases in incidence at age 65 and older. It has been postulated that 
there might be an interaction between age, neuropathology and comorbidity, and that 
age alone would probably be a less prominent risk factor once other risk factors and 
comorbidity are taken into account [4].  
Genes and genetic variants are risk factors for dementia development. Generally, 
genetic risk in AD is by far the most studied. Genetically, AD can be subdivided into 
the rare (accounting for less than 1% of cases) autosomal dominant familial forms 
often causing early-onset AD, and the multifactorial sporadic form with several 
associated genes [85]. The autosomal dominant forms are caused by mutations in 
amyloid precursor protein, presenilin 1 or presenilin 2 genes resulting in symptom 
manifestation before the age of 65 years [86].  
Sporadic AD has no known causative gene mutations. However, genome-wide 
association studies have identified multiple novel risk genes for AD pathology. Some 
of these genes could be linked to the amyloidogenic pathway, while others are 
involved in the immune system, synaptic functioning, and lipid metabolism which 
also show the relevance of these pathways in AD [85, 87].  
Importantly, apolipoprotein E (APOE) ε4 gene represents the strongest genetic risk 
factor for sporadic AD [43]. The multifunctional APOE protein is encoded by the 
APOE gene which exists as three alleles; ε2, ε3, and ε4 producing 6 genotypes, where 
the resulting proteins; APOE2 APOE3 and APOE4 only differ in one or two amino 
acids [88]. Of the three alleles of the APOE gene, the ε3 is most common and neutral 
regarding risk for AD, while the APOE ε4 allele has been shown to be the major 
genetic risk factor of AD, whereas the APOE ε2 allele decreases the risk [89, 90]. 
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However, the APOE ε4 cannot alone be used as a tool for diagnosing AD as it is 
neither sufficient nor necessary for the development of AD [91].  
Genes related to LBD are not as not as thoroughly mapped as those related to AD, 
however studies, including recent genome-wide association studies performed in 
Norwegian and European cohorts reported the APOE ε4 allele and the 
glucocerebrosidase (GBA) gene as significantly associated with DLB [92, 93].  
1.5.2 Modifiable risk factors 
There is an expectation of future disease-modifying treatments for dementia. 
However, a need for its effective prevention still exists, as prevention is generally 
better and often cheaper. Currently, intervention and treatment strategies focusing on 
modifiable environmental and lifestyle factors are the only available approaches to 
reducing rates of dementia. Although not all dementia risk factors are modifiable, 
previous calculations have shown that up to 40 % of dementia cases may theoretically 
be preventable [9]. The latest Lancet Commission: “Dementia prevention, 
intervention and care” recently published a list of 12 potentially modifiable risk 
factors that can contribute to increased dementia risk, including hearing loss, less 
education, traumatic brain injury, low social contact, depression, physical inactivity 
alcohol consumption and air pollution in addition to vascular risk factors such as 
hypertension, smoking, obesity, and diabetes [9]. The recognition of all of the 
previously mentioned risk factors are of importance, however this thesis focuses on 
some vascular risk factors, which will be described in further detail in the following 
section.  
A number of mid-life vascular risk factors such as hypertension, overweight, 
smoking, diabetes mellitus, and hypercholesterolemia have been identified as risk 
factors for late-life dementia in general, however most knowledge exists about the 
risk factors for AD [4, 9, 12, 94, 95]. Of note, vascular risk factors are unlikely to 
occur isolated but might interact (e.g. metabolic syndrome) and for most of these risk 
factors, the mediating pathways are not completely known, whether they are acting 
on the amyloid process, on the reserve capacities, or on the inflammatory pathway 
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[43]. Although midlife is poorly defined, midlife has been defined as 45–65 years and 
later life as older than 65 years in published works on dementia risk [4].  
1.5.3 Vascular risk factors  
Smokers are at a higher risk of dementia compared to non-smokers, possible due to 
the link between smoking and cardiovascular disease, and smoking cessation, even at 
older age reduces this risk [4, 9]. However, there are some bias and uncertainty in the 
association between smoking and risk of dementia as smokers also have higher risk 
of death before the age at which they might have developed dementia [9]. 
Epidemiological studies report mid-life hypertension to be a risk factor for cognitive 
decline, MCI and dementia, not only VaD, but also AD [25, 26, 96-98]. In the 
Framingham Offspring cohort comprising 1440 people, elevated systolic blood 
pressure (≥140 mm Hg in midlife; mean age 55 years) was associated with an 
increased risk of developing dementia and the risk increased further if hypertension 
persisted into later life [98]. Of note, among those not having hypertension, a steep 
decline in blood pressure during mid- to late life was associated with an increased 
dementia risk highlighting the potential cognitive benefits of lower blood pressures in 
midlife, but also suggesting that declining blood pressure in older adults with 
prehypertension or normotension may be a risk marker for dementia [98].  
Hypertension is an established as a risk factor for cerebrovascular disease, as it 
affects the cerebral vasculature and is a risk factor for both extracranial and 
intracranial atherosclerosis and cerebral infarction. Even relatively small volumes of 
damage in brain regions involved in cognition, i.e. hippocampus, medial thalamus 
and frontal lobe can produce cognitive dysfunction [99]. Importantly, hypertension is 
a risk factor for small vessel disease, which is parenchymal lesions caused by 
abnormalities in the small vessels. Further, small vessel disease is associated with 
cognitive impairment [99]. The features of small vessel disease visible on 
conventional MRI include white matter hyperintensities (WMHs), small infarcts, 
dilated perivascular spaces, microbleeds and brain atrophy [100]. WMHs appear as 
bright areas in the more gray-appearing normal brain tissue on MRI scans, and recent 
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pathology studies have, interestingly, found an association between WMHs and AD 
pathologies [101]. 
Being ambitious about treating hypertension in middle aged and older people without 
dementia to reduce dementia incidence is recommended [9]. A meta-analysis 
concluded that using any antihypertensive medication in people aged 55 years and 
older with high blood pressure reduced the risk for developing dementia. However, 
there were no significant differences by use of a specific drug class [102].  
Diabetes mellitus has been found to be a risk factor for future AD and dementia 
development [4, 103]. In a pooled meta-analysis diabetes mellitus type 2 was 
associated with an increased risk of any dementia and the risk of dementia increased 
with the severity and duration of diabetes. For VaD, the additional risk was found to 
be greater in women [104]. Diabetes mellitus type 2 appears to be associated with PD 
and neurodegenerative dementias, possibly through peripheral and cerebral insulin 
resistance which in turn results in altered autophagy, cell proliferation and increased 
inflammation [95]. Also, drugs used in diabetes treatment have shown positive effects 
on neurodegenerative processes and on clinical outcome, regarding memory and 
cognition [95]. Diabetes mellitus type 2 has been shown to be a risk factor for AD 
and dementia not only through increased risk of small vessel disease and increased 
risk of both cardio- and cerebrovascular disease, but also through insulin resistance 
and chronic inflammation [54, 105, 106]. Although diabetes mellitus type 2 is a risk 
factor for development of future dementia it is uncertain whether any particular 
medication ameliorates this risk [9]. 
Obesity in midlife has been been found to be associated with an increased risk of 
dementia and AD later in life [27]. A review of 19 longitudinal studies including 
middle aged people followed up for up to 42 years reported obesity (Body mass index 
(BMI) ≥30) but not being overweight (BMI = 25–30) to be associated with late-life 
dementia. Of note, the association between midlife underweight and dementia were 
inconsistent [107]. Several epidemiological studies have concurred in that there is a 
decline in BMI in the years prior to dementia [108, 109]. As part of metabolic 
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syndrome, obesity has been shown to increase peripheral inflammation, and 
interestingly it is suggested that excessive inflammatory mediators produced by 
adipose tissue during metabolic syndrome affect the brain, stimulating microglia and 
causing synaptic alterations, and possibly initiating the accumulation of Aβ [54, 110]. 
These findings reinforce the complexity of the relationship between inflammation, 
genetic and lifestyle risks, possibly acting cumulatively to increase the risk of 
developing AD.  
Atherosclerosis is also a chronic inflammatory process. There is a causal relationship 
between plasma cholesterol levels and atherosclerosis, a common risk factor for both 
cardiovascular- and cerebrovascular disease, as well as AD and dementia [111-113]. 
Further, in peripheral tissue APOE proteins are mainly produced by the liver and 
regulates lipid homeostasis by mediating lipid transport between tissues. APOE ε4 
has been shown to be associated with atherosclerosis, and to be a risk factor for 
coronary heart disease thus contributing to an increased risk of AD [90]. 
Interestingly, similar to the observations of hypertension and obesity, the relationship 
between serum total cholesterol and dementia seems to be bidirectional as high 
midlife total cholesterol is a risk factor for late-life dementia and AD [97], however 
high total cholesterol in late life has been shown to be associated with decreased 
dementia risk [114]. Decreasing serum total cholesterol after midlife may reflect 
ongoing disease processes and may represent a risk marker for late-life cognitive 
impairment [115].  
Noteworthy, the brain is a highly lipid-enriched organ, requiring cholesterol, and 
other lipids for the long expansions of neurons and myelin construction, and the 
remodeling needed in relation to recovering from damages, aging-related 
deterioration, and disease [116]. Lipid alterations have been reported to be related to 
neurodegenerative processes, particularly in AD by increased Aβ production [31-33]. 
As lipid alterations in AD is a subject of this thesis, it will be described in greater 
detail below. 
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1.5.4 Lipid alterations in Alzheimer’s Disease 
Lipids are obtained through diet or synthesized and metabolised by enzymes, and are 
estimated to include at least 10,000 - 100,000 distinct species in the human lipidome 
[117]. Using biochemical approaches, lipids can be sorted according to the 
comprehensive classification system devised by LIPID Metabolites And Pathways 
Strategy (MAPS), which classify lipids into eight major categories: fatty acyls, 
glycerolipids, glycerophospholipids, sphingolipids, saccharolipids, polyketides, 
isoprenols, and sterols where each category can also be further subdivided into 
subclasses [118] resulting in a wide diversity of lipid families where the roles of some 
are still poorly understood.  
In the central nervous system cholesterol is produced in astrocytes, and APOE 
functions as a transporter of cholesterol to neurons via APOE receptors. Although the 
exact mechanism of APOE proteins is not known, it has been shown that APOE4 has 
implications for the major hallmarks of AD including deposition and clearance of Aβ 
peptide plaques, tau phosphorylation and neuroinflammation [90]. Interestingly, a 
recent study of 152 non-demented participants found APOE ε2 carriers to have 
elevated baseline phospholipids, especially phosphatidylethanolamine in plasma. 
Further the high baseline phosphatidylethanolamine predicted protection against 
cognitive decline after six years [119], suggesting a possible pathomechanism 
involved in AD risk by modulation of plasma lipids by APOE genotype.  
The majority of lipids reside in cell membranes forming a lipid bilayer and carry out 
important functions of cell membranes such as cellular transport, energy storage, 
modulator for transmembrane proteins, and act as signaling molecules [120, 121]. 
The main lipid classes in the brain found to be disrupted in AD include cholesterol 
phospholipids, sphingolipids, and glycerolipids, mainly localized to myelin and 
neuronal membranes where they are constituents of the cellular membrane [32, 122].  
The mechanisms by which lipids could be involved in AD pathology are unclear. The 
brain is rich in cholesterol which has important roles in the synthesis, deposition, and 
clearance of Aβ [123]. However, Aβ can also perturb cholesterol and lipid 
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metabolism [32]. Oxysterols, derivatives of cholesterol which pass the blood-brain 
barrier are thought to reflect cerebral cholesterol turnover, and the role of oxysterols 
in AD pathogenesis has been strongly supported by their involvement in modulating 
neuroinflammation, Aβ accumulation, and cell death [123].  
Further, membrane microdomains, so-called lipid rafts, are found to be enriched with 
cholesterol, sphingolipids, including sphingomyelin, and glycerophospholipids, and 
to anchor transmembrane proteins and signalling molecules such as ion-channels 
[124]. The proteins amyloid precursor protein, β-secretase, and components of the γ-
secretase complex taking part in the amyloidogenic pathway of AD described in 
section 1.4.2 are transmembrane proteins. Hence changes in the cholesterol and the 
sphingolipids may lead to changes in the composition and function of the lipid raft, 
and might thus contribute to changes in β- and γ-secretase activities and consequently 
affect the production of Aβ42 and disease such as AD [32, 125].  
The possible implications of sphingolipids in AD and neurodegeneration have 
previously been explored in several studies [126-128]. The sphingolipids are 
associated with neuroinflammation, oxidative stress and apoptosis [126, 129]. 
Further, the homeostasis of membrane sphingolipids in myelin and neurons have been 
found to be essential to prevent the loss of synaptic plasticity, cell death and 
neurodegeneration [126]. Several bioactive molecules belong to the sphingolipids, 
including sphingomyelin, ceramide, sphingosine, and sphingosine-1-phosphate. 
Sphingomyelin can be hydrolysed to produce ceramide which can then be 
metabolised to sphingosine and further phosphorylated to produce sphingosine-1-
phosphate. Ceramide can also be produced by alternative pathways and synthesised 
de novo [130].  
It has been postulated that studying changes in brain lipid profiles could give insights 
not only into the pathogenesis of AD but also further the detection of potential 
markers for early disease diagnosis and monitoring for progression [125]. The 
relationship between lipid changes and cognitive impairment in AD have been 
studied in blood, CSF and brain tissue [32, 122, 128]. Despite only a few studies 
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having investigated lipid changes in CSF, sphingomyelin has been found to be 
elevated in CSF in AD patients, while phospholipids have mostly been unchanged or 
increased [122, 131-133].  
Several clinical studies have reported altered blood lipid levels in sporadic AD 
pathology [32, 130, 134-137]. However, as previously stated by Wong et al. this field 
of exploration in research is still fairly new, and it is difficult to establish consensus 
in findings based on the number of different approaches and techniques applied 
across different laboratories [32]. Previous reviews have concluded that future studies 
should be done in well characterised longitudinal cohorts aiming to link blood-based 
lipidomics changes with neuropathology and integrate findings with known genomic 
and proteomic alterations in AD [32, 138].  
 Progression of cognitive impairment 
Cognitive impairment, including dementia, can result from several different 
underlying diseases with different rates of progression. The percentage of patients 
diagnosed with MCI converting to dementia is a common way to report progression 
of cognitive impairment. Although estimates vary widely with study population and 
criteria used for MCI diagnosis, most studies report a rate of progression from 20 to 
40%, with an annual rate of 5–17% [139, 140].  
Although neurodegenerative diseases such as AD and LBD are chronic irreversible 
diseases where progression is expected in all patients, there is a large inter-individual 
variation in the rate of cognitive decline [43, 79, 80, 141, 142]. As there are no 
reliable predictors of neurodegenerative disease course, evidence about contributing 
factors associated with progression of cognitive decline are of interest as they would 
possibly enhance the understanding of the disease mechanisms, as well as enabling 
interventions to slow rate of decline. A previous study found that diabetes and 
prediabetes increased the risk of conversion from amnestic MCI to AD dementia. 
Further, diabetes, prediabetes, metabolic syndrome, and the presence of 
neuropsychiatric symptoms were found to increase the risk of progression from MCI 
 33 
to all-cause dementia [17]. A retrospective, longitudinal, observational study using an 
unselected sample to test for associations between comorbidities in patients with MCI 
due to AD, VaD and LBD found 37.4% of the MCI patients to progress to dementia 
with a mean follow-up period of 27.09 ± 15.09 month, where the proportion of 
conversion to dementia was 39.9% in AD, 38.2% in VaD, and 27.1% in LBD [143]. 
Older age at onset, female sex, and a greater Clinical Dementia Rating Scale Sum of 
Boxes (CDR-SB) were significantly associated with a higher risk of converting from 
MCI to dementia both in the whole group, and also in subgroups related to dementia 
diagnosis [143].  
The Norwegian Progression of Alzheimer’s Disease and Resource use (PADR) study 
reported the annual proportion converting from MCI to AD to be 27% with an annual 
progression of AD of 1.6 points on the CDR-SB and mean annual decline in Mini 
Mental State Examination (MMSE) score of 1.9 [144, 145].  
The role of APOE ε4 as a risk factor for AD is well established and it significantly 
lowers the age of AD onset. In addition APOE ε4 has been reported to be associated 
with increased risk of progression from MCI to AD-type dementia [90]. Controversy 
exists however as to whether APOE is associated with the rate of progression of 
cognitive decline in AD after its onset [91, 146].  
Regarding dementia progression, little is known about this on the individual level. 
Dementia progression is heterogeneous both between and within persons with 
dementia, which can be explained by both disease and person characteristics [147, 
148]. A Norwegian cohort study, with a median follow-up time of 4.3 years found 
DLB to decline faster (annual decline 4.4 points on MMSE) compared with AD (3.2 
points on MMSE) concluding that from the mild dementia stage, patients with DLB 
have a more rapid cognitive decline than in AD [141]. In addition DLB has been 
shown to have a poorer prognosis than AD on several other important outcome 
measures, including higher carer stress, increased health care costs, shorter time to 




Identification of preventable or treatable predictors likely to accelerate progression of 
cognitive impairment could be of importance, as this might possibly slow down 
cognitive decline. If so, it might reduce the costs of health care, and possibly reduce 
carer burden [4]. As part of this thesis focuses on progression of dementia related to 
the effect of vascular risk factors; this will be further addressed below. 
1.6.1 Vascular risk factors and dementia progression 
Studies available at the start of this doctorial project and during the writing of paper I 
were mainly focused on vascular risk factors associated with AD dementia 
progression. Findings from a systematic review suggested an association between 
LDL-cholesterol and the progression of dementia, while inconsistent results were 
found for other vascular risk factors. Of note, the review with the aim of evaluating 
whether vascular risk factors (hypertension, hypercholesterolemia, diabetes mellitus, 
overweight, and smoking) were associated with the progression of dementia, reported 
findings from AD dementia mainly, and to some extent VaD [30, 153], although 
“lewy bodies” were among the published search words [30]. Of note, in a cross- 
sectional analysis of late life cardiovascular factors and their relation to clinically 
defined neurodegenerative diseases, a specific association of AD and DLB with 
cardiovascular factors were found, especially with respect to BMI [154]. Further, a 
study from Poland examining the influence of vascular risk factors, on the survival 
rate of patients with DLB and AD reported diabetes mellitus, and to a lesser extent 
hypertension to shorten the survival time for AD cases, however no influence on 
DLB cases was found [155]. 
Although several studies have been published on the potential association of vascular 
risk factors and dementia progression no firm conclusion can been drawn [30]. The 
results of studies on various vascular risk factors, and in some cases, a sum score of 
these, and their association with dementia progression are summarised in Table 1. 





Most studies reported findings of dementia progression due to AD except one 
reporting on AD and VaD [153]. As evident in Table 1, the findings are conflicting. 
Although some studies reported an association between a single vascular risk factor, 
or a sum score of these, and an effect on dementia progression, most studies reported 
no associations. The conflicting results could have a number of explanations. Most 
important factors probably being different selection criteria for the study participants 
including age, diagnosis criteria, degree of dementia and definition of the various 
vascular risk factors. Further, there are differences in methodology, lengths of the 
different studies, and choice of outcome measure, although most studies used either 
MMSE, CDR or both as outcome measures. Most studies show results on a single 
vascular risk factor, but potentially a combination of vascular risk factors would be 
associated with a faster cognitive decline. However, as table 1 shows, also here the 
results are conflicting, probably for the same reasons as mentioned above regarding 
methodology. 
Further studies are therefore needed in a well-characterised cohort, preferably of 
longer time duration. Also studies are needed to examine the possible effect of 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Nutritional factors may modify the risk for dementia [14]. Polyphenols and 
flavonoids are among the nutritional factors potentially influencing cognitive decline 
and dementia, possible due to a number of dementia relevant mechanisms, including 
on inflammation, oxidative stress, lipid metabolism, glucose metabolism and vascular 
function [18].  
Anthocyanins constitute a subclass of flavonoids which again is a subgroup of the 
polyphenols, and are characterised structurally by the presence of two phenyl rings 
separated by a hetero-cyclic ring [18]. The anthocyanins are water soluble natural 
color pigments with low to no toxicity, present in most plants and foods such as 
berries, including blueberries, and fruits [180]. A total of about 5-600 different 
anthocyanin molecules have been identified, and information regarding the content of 
anthocyanins in food can be found in an online phenol-explorer [181].  
Anthocyanins have been reported to have properties as antioxidants, which is 
regulated by the chemical structure involving free hydroxyl (⋅OH groups) around the 
pyrone ring, where the number of ⋅OH groups scattered throughout the molecule’s 
structure determines the potency of its antioxidant activity [182]. The antioxidant 
mechanisms include the suppression of reactive species formation through enzyme 
inhibition, and the sequestration of trace elements involved in the production of free 
radicals, in addition to act as reducing agents in the electron-transfer reaction 
pathway, donating electrons to the free radicals with unpaired electrons [182, 183]. 
Cellular studies have shown the neuroprotective effect of anthocyanins and 
metabolites in human neuronal cells (SH-SY5Y) against hydrogen peroxide-induced 
oxidative stress [184] and modulation of the mitochondrial network [185]. 
Importantly, anthocyanins have been found to cross the blood-brain barrier [186] and 
to have anti-amyloid effect, possibly through inhibition of Aβ protein spontaneous 
aggregation into oligomers and preventing the fibrillogenesis of Aβ proteins, 
counteracting their toxicity and their triggering of neuroinflammation [187-190]. Of 
note, several preclinical studies have provided evidence for the potential ability of 
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anthocyanins to inhibit neuroinflammation through an attenuation of microglial 
activation and associated cytokine release, in addition to counteracting 
neuroinflammation related to oxidative stress [191, 192]. 
Studies have reported anthocyanins to have anti-inflammatory effects, possibly by 
suppressing pro-inflammatory mediators through the inhibition of nuclear factor 
(NF)-κB [182, 193]. Further, studies have suggested that anthocyanins could reduce 
pro-inflammatory markers such as tumor necrosis factor alpha (TNF-α) monocyte 
chemoattractant protein (MCP-1) and IL-6, which have been shown to play a role in 
the pathogenesis of obesity and increasing the risk of other associated metabolic 
diseases including insulin resistance, diabetes mellitus type 2, atherosclerosis and 
cardiovascular disease [193-195]. Of note, a meta-analysis of 32 RCTs found that 
anthocyanin supplementation had no relevant effects on inflammation markers, but 
significantly improved fasting and two hour postprandial glucose, HbA1c, total 
cholesterol, and LDL-cholesterol [19].  
The positive effects of anthocyanins have been found to be on cardiometabolic 
health, and cardiovascular risk factors [19]. Anthocyanins may also protect against 
cardiovascular related cognitive decline by mechanisms reported to be through the 
modification of a number of risk factors common to neurodegeneration due to AD, 
VaD, and cardiovascular disease, such as improving lipid profile, decreasing risk of 
diabetes mellitus type 2 and dysfunctional glucose metabolism, and improving 
endothelial and vascular function [20-24, 196]. Anthocyanins have in several studies 
been reported to improve endothelial and vascular function, possibly through nitrogen 
oxide bioactivity [22, 23, 196-198].  
There has been increased interest in- and research on the potential of flavonoids and 
anthocyanins to improve memory, learning, and general cognitive ability [199]. A 
study of the Framingham Offspring Cohort implied that higher long-term dietary 
intake of flavonoids is associated with lower risk of AD [200].  
Over the last years several clinical studies have been done evaluating the effect of 
anthocyanins on cognitive function [201]. The first controlled human trials examining 
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neurocognitive response to dietary intervention were conducted in 2010 by Krikorian 
et al. reporting improved cognitive performance in elderly adults after 12 weeks of 
daily intake of Concord grape or blueberry juice [202, 203]. In another study of 
Concord grape juice relatively greater brain activation in anterior and posterior 
regions of the right hemisphere was observed with functional MRI in the grape juice 
treated subjects, which would be consistent with vascular benefit and greater 
hemodynamic response associated with increased neuronal activity [204]. 
Randomized, double-blinded, placebo-controlled studies have also reported positive 
effects on cognitive functions in older adults. Interestingly, relatively modest benefits 
were found in cognitively unimpaired older adults compared with benefits measured 
in participants with mild cognitive impairment [205, 206]. The cognitive functions 
that improved were executive function [205], and benefits in memory performance 
and subjective improvements in everyday function [206]. Bowtell et al. reported 
evidence suggesting improvement in working memory after blueberry versus placebo 
supplementation, and also that supplementation with an anthocyanin-rich blueberry 
concentrate improved brain perfusion and activation in brain areas associated with 
cognitive function seen on MRI in healthy older adults [207]. Another study found 
that regional blood oxygen level-dependent activity detected by functional MRI was 
enhanced in the subjects taking blueberries, but not in those taking placebo during a 
memory test in subjects with mild cognitive impairment [208].  
Of note, the previously published studies examining the effects of anthocyanins on 
cognition have methodological limitations, including small sample sizes and short 
duration. A further limitation is the heterogeneity in sources, concentration, and dose 
of anthocyanin supplementation being used. Hence, it is not clear whether these 
promising preliminary findings can be translated into clinically meaningful effects, 
that is, reducing the rate of cognitive decline and risk of dementia. 
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 Literature search  
The literature searches were generally done in PubMed and in some cases Embase 
and Google Scholar, using the same identical search terms and combination of search 
terms. In a few cases searches were done in the Cochrane Library. The last 
comprehensive literature search for this thesis was done in March 2020. Additional 




2. Aims and hypotheses 
 General aim 
The general aim of this thesis was to increase knowledge about the role of vascular 
risk factors, lipid alterations and anthocyanin supplementation with respect to 
development and progression of cognitive impairment in a population of people with 
mild dementia or at increased risk of dementia. 
 Specific aims 
1) To examine the potential effects of vascular risk factors on disease progression 
in older adults with mild dementia due to AD or with mild LBD. 
2) To explore plasma lipid profile in mild cognitive impairment due to AD, and 
its association with cognition. 
3) To explore the effects of anthocyanins on mechanisms relevant for cognitive 
decline in adults and older adults with increased risk of dementia. 
 Hypotheses 
a) Vascular risk factors (hypertension, overweight, smoking, diabetes mellitus, 
hypercholesterolemia) are associated with a faster cognitive decline in people 
with mild dementia due to AD or with mild LBD. 
 
b) People with MCI due to AD have a specific plasma lipid profile which is 
associated with cognitive impairment. 
 




3. Materials and Methods 
 
This thesis is based on three papers which in turn are based on data from three 
different studies. Table 2 provides an overview of the papers. 
Table 2: Overview of the papers in the thesis. 
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20 
16 weeks Simple 
comparison 
AD = Alzheimer’s disease, LBD = Lewy body dementia, MCI = mild cognitive impairment, 
MCI-Aβ42pos = MCI with AD pathology, MCI-Aβ42neg = MCI without AD pathology, VRFs = 
vascular risk factors, CAD = Non-obstructive coronary artery disease, DemVest = Dementia 
study of Western Norway, DDI = Dementia Disease Initiation 
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Both the Dementia study of Western Norway (DemVest) [209] and the Dementia 
Disease Initiation (DDI) [210] studies are longitudinal observational studies, while 
the Anthocyanin study is an open label pilot study. A further description of the study 
participants, including inclusion and exclusion criteria will be given in the Materials 
section (3.1), while section 3.3 provides a description of the clinical assessments in 
the studies. The cognitive tests used for cognitive assessment and as primary or 
secondary outcome measures in the different studies are described in more detail 
below, in the Cognitive assessment scales section (3.2). 
 Materials 
3.1.1 The Dementia study of Western Norway  
In paper I, participants were included from the DemVest study, a prospective cohort 
study of older persons with a first time diagnosis of mild dementia, with a particular 
focus on LBD, and inclusion in the period 2005 -2013 (n=266) [209]. During the 
main inclusion period in DemVest from March 2005 to March 2007 all referrals to 
the outpatient clinics in old age psychiatry and geriatric medicine in the counties of 
Rogaland and Hordaland in western Norway were screened for a first time diagnosis 
of mild dementia. A letter was sent to all general practitioners in the area, asking 
them to refer new cases with mild dementia to the study. The three neurology 
outpatient clinics in the region were contacted, and asked to refer patients with newly 
diagnosed dementia to the study. In order to increase the number of LBD cases, 
patients with DLB and PDD were selectively recruited from April 2007.  
Inclusion criteria in the DemVest study was a first-time diagnosis of mild dementia. 
Further, the patients had to have a MMSE score ≥ 20 [211]. 
Exclusion criteria were not having a dementia diagnosis or having acute delirium, 
terminal illness, previous bipolar disorder or psychotic disorder, or those recently 
having been diagnosed with a severe somatic illness which according to the clinician 
would significantly impact on cognition, function or study participation.  
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Participants included in paper I were those diagnosed with dementia due to AD or 
LBD, taking into account the diagnostic changes made in the 5 year follow-up 
reevaluation [141] and the reevaluation of the 46 brain autopsies available at the time. 
In addition an MMSE score of at least 20 was required for inclusion. 
3.1.2 Dementia Disease Initiation  
In paper II, the participants in this study were drawn from the Norwegian multicenter 
DDI study [210], a nationwide ongoing longitudinal cohort study for early detection 
of at-risk Alzheimer’s disease cases, led from the Department of Neurology, 
Akershus University Hospital, Norway.  
During the inclusion period from January 2013 to date, subjects with self-reported 
cognitive reduction and healthy controls have been recruited as self-referrals from 
advertisements in media, newspapers and news bulletins, and referral from General 
Practitioners to the local memory clinic. Cognitively healthy controls were also 
recruited among spouses of patients with cognitive disorder and from patients who 
had completed a lumbar puncture for orthopedic surgery. Participants in the age-
group between 40 and 80 were included, and only those with a native language from 
one of the three Scandinavian countries. Exclusion criteria were brain trauma or brain 
disorder, which included dementia (CDR > 0.5 [212]), clinical stroke, severe 
psychiatric or somatic disorder that might influence cognitive functioning, or 
intellectual disability or other developmental disorders. 
Out of the 658 participants available from the DDI cohort as of January 2019, 50 
participants with MCI due to AD (based on CSF measurements where the CSF Aβ42 
measurements were dichotomized using a cutoff of ≤ 708 ng/L (further described in 
3.3.2)) were identified as MCI Aβ+. These participants were sex and age matched by 
manual matching with 50 Aβ- MCI participants and 50 normal controls. One 
participant in the MCI group was later reclassified as not having MCI and therefore 
excluded.  
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3.1.3 Anthocyanin study 
In paper III, the participants were included in the Anthocyanins study, which is an 
open-label pilot study of people with increased risk of dementia. Recruitment of the 
study participants took place in the period of 2015 and 2017 at Stavanger University 
Hospital in Stavanger, Norway. The participants of the anthocyanin group were 
recruited during the period May 2015 to September 2016. The normal controls were 
recruited in the period December 2016 to February 2017. Participants eligible for this 
study were patients from the outpatient memory clinic diagnosed with MCI or mild 
dementia according to the ICD-10 criteria [35] and/or patients from the intervention 
cardiology outpatient clinic diagnosed with stable non-obstructive coronary artery 
disease at coronary angiography. Participants in the DDI study [210] with a diagnosis 
of MCI were also recruited to participate in the study. Normal controls were recruited 
among the staff at Stavanger University Hospital and through acquaintances.  
Both the anthocyanin group and the normal control group had to have age ≥ 50 years 
and being on stable medication, including nutraceuticals for the past 3 months. 
Exclusion criteria were moderate or severe dementia (a MMSE [211] score < 24), 
clinically significant depression (a 15–item Geriatric Depression Scale (GDS-15) 
[213] score ≥7), heart failure in need of treatment, unstable coronary artery disease, 
having taken the anthocyanin supplement Medox® (Please see section 3.3.3 for 
description) during the past 3 months, inflammatory illnesses such as rheumatoid 
arthritis and other severe illness with < 5 years expected survival and using Warfarin, 
heparin or non-vitamin K antagonist oral anticoagulants.  
 Cognitive assessment scales 
In this section the cognitive assessment scales, i.e. the ones that have been used in the 
MCI or dementia diagnosis in the studies and/or used as outcome measure of the 
papers of this thesis are described in more detail. 
 47 
Mini-Mental State Examination (MMSE) 
The MMSE is widely used as a screening tool for cognitive function, both in clinical 
practice and research where it is used to measure cognitive change over time [214, 
215]. The test consists of 20 items testing cognitive function, that is, orientation, 
memory, attention, calculation, language and construction giving a total of 30 point 
where higher score indicates better cognitive functioning [211]. Due to limited 
response ranges, the MMSE test have floor and ceiling effects, which limits the 
capability of detecting both advanced dementia and early cognitive change. Further, 
education and age, as well as language and sensory functions i.e. hearing and vision 
may influence the result of the test [214]. Of note, the test is administrated directly to 
the patient and therefore daily fluctuations in the mood of the patient, or motivation 
to respond in the test situation might influence the test result. 
The test can be used in settings with repeated testing as it gives specific instructions 
upon retesting, however there is a risk of practice-effects due to repeat exposure to 
the test materials [215]. As a screening tool the MMSE test has been shown to have 
good reliability and validity, however it is not recommended to be used alone in 
diagnosing dementia [214, 216].  
Clinical Dementia Rating Scale 
The Clinical Dementia Rating Scale (CDR) scale is a well-validated, widely used tool 
originally developed for measuring AD dementia severity and has shown good inter-
rater reliability [217]. The CDR gives a broader assessment of both cognitive and 
daily functioning and is obtained through interviews of both patients and a next of 
kin, thus not influenced by mood or daily fluctuations [218]. The six different areas 
examined in this scale are memory, orientation, judgment and problem solving, 
community affairs, home and hobbies, and personal care with global scores 0-3 where 
0 denote normal functioning while 1,2 and 3 indicate mild, moderate, and severe 
dementia, respectively. A score of 0.5 translates into uncertain or subtle cognitive 
impairment. The global score is calculated based on an algorithm that weights 
memory as the primary domain. 
 48
For research, the CDR sum of boxes (CDR-SB) is used where the score represents the 
arithmetic sum of the category ratings across the six domains of functioning and 
serves as a means of quantifying the overall level of function. The score is obtained 
by summing each of the domain box scores (0-3), giving a total score of 0-18, where 
lower score indicates higher functioning [217]. The CDR-SB score has been reported 
to offer several advantages over the global score, including increased utility in 
tracking changes within and between stages of dementia severity, due to the increased 
range of values [219]. 
The Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD) wordlist memory test (WLT) 
Verbal memory function was assessed using the Norwegian adaptation of the Ten 
Word List Learning and Recall from the the Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD) neuropsychological battery [220], a three part test 
where the participants are to: 1. Learn a list of 10 words presented in three trials 
(word list learning), giving a potential maximum of 30 points. 2. Recalling after about 
10 minutes the 10 words from the word list learning task (word list delayed recall), 
giving a maximum of 10 points. 3. Recognition of the presented 10 words among 
other distracting words (word list delayed recognition), giving a maximum of 20 
points [221]. The scores are interpreted based on normative data as for all tasks, and 
the score requirements increase with education and decreases with age. The test 
norms used in paper III was according to Sotanemi et al. [222] while demographically 
adjusted norms were used in paper II [223]. 
CERAD Composite 
In paper II the CERAD Composite was constructed from the subtests of the CERAD 
word list memory test in order to construct a memory composite. Following an 
established method for cognitive composites [224, 225] the CERAD Composite 
included CERAD subtest total learning, recall and recognition. Similar CERAD 
memory composite scores have previously been shown accurate in detecting 
prodromal AD [226]. Briefly, raw scores for CERAD subtest total learning (30 
items), recall (10 items) and recognition (20 items) were standardised to scores 
 49 
between 0 and 1. These scores were summarized and averaged to compute a 0 – 1 
standardised composite score. Further, in order to provide normative adjustment for 
pertinent demographics, i.e. age and education, a regression-based norming procedure 
[223, 227] was employed using n=146 healthy controls from the DDI cohort [210]. 
Standardised T-scores were then calculated for the participants in the study of paper 
II. (See paper II [2] for full description) 
The Visual Object and Space Perception Battery 
The Visual Object and Space Perception Battery (VOSP) silhouettes is a measure of 
visuoperceptual ability [228]. The participant are shown silhuettes of animals, 15 in 
total, and are to name them. After, the participant is asked to name 15 different 
everyday items. For both sections the test is ended if the participant makes 5 mistakes 
in a row. One point is given for each correct answer. Age adjusted norms are 
provided in the VOSP test manual [228]. 
The Controlled Oral Word Association Test 
The Controlled Oral Word Association Test (COWAT) [229] is a measure of 
phonemic verbal fluency. The patient is asked to name as many words as possible on 
the letters F, A, and S. A 60 second limit is set for each letter. In paper II 
demographically adjusted norms from Heaton et al. were used [230], while in paper 
III unadjusted norms were used. 
Trail Making Test A and B  
The Trail Making Test (TMT) A and B are tests where part A assesses visual 
scanning and psychomotor speed while part B assesses the same abilities and in 
addition attention shifting [231]. Part A consists of 25 numbered circles where the 
participants are instructed to draw a line connecting the circles from 1 to 25 as fast as 
possible. Part B consists of 25 circles with numbers 1-13 and letters A-L. The 
participants are instructed to connect the circles, alternating between numbers and 
letters. For both parts the score is given as time (seconds) used to finish each part, 
where shorter time indicates better psychomotor speed and executive functions [231]. 
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The results of the TMT may be influenced by age and education [232], and 
demographically adjusted norms were used in paper II [230]  
Stroop Golden Test 
The Stroop Golden test [233] is a test used to evaluate cognitive speed and inhibition 
[234] consisting of 3 parts, i.e. a word naming score, a colour naming score and a 
word-colour naming score, where the word-colour score is determined using a sheet 
of paper where colour words are written with incongruous ink colours. The 
participants are required to name the colour of ink in which the word is written rather 
than the word itself. The 3 scores are determined by the number of words the 
participants are able to read in 45 seconds in each part [235]. 
 Clinical assessment 
3.3.1 The Dementia study of Western Norway  
At baseline, the patients underwent a comprehensive clinical evaluation by a study 
physician (old age psychiatrist, neurologist or geriatrician) with help from a research 
nurse. The baseline assessment included a complete physical examination and 
medical history by the study physician who also recorded the medication use. Other 
data collected according to the protocol included age, sex, weight, height, smoking 
status, electrocardiogram, blood tests, including APOE genotype analyses as 
previously described [236] and CSF biomarker (t-tau, p-tau and Aβ42) analyses as 
previously described [237]. 
The dementia diagnosis was made according to the Diagnostic and Statistical Manual 
for Mental Disorders, 4th edition (DSM-IV) [37]. The AD dementia diagnosis was 
made according to the criteria of the National Institute of Neurological and 
Communicative Disorders and the Stroke-Alzheimer’s Disease and related Disorders 
Association [61], while a DLB diagnosis was made according to the revised 
consensus criteria [77] and a PDD diagnosis according to the recommendations from 
the Movement Disorder Society Task Force [79].  
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Standardised instruments including MMSE [211], Informant Questionnaire on 
Cognitive Decline in the Elderly (IQCODE) [238] and the CDR scale [219] were 
employed in the dementia diagnostic workup. Additionally a battery of 
neuropsychological and psychiatric tests were performed, please see reference [209].  
The diagnostic criteria were independently applied by two of the researchers at 
baseline and the final diagnosis was made by consensus in cases of disagreement, and 
in the cases where the patients were fulfilling more than one diagnostic criterion.  
After the baseline evaluation the participants are followed up annually, however with 
a less extensive protocol, until death. In order to harmonize intra- and inter-rater 
reliability at each centre and between centres, biannual meetings were held for the 
first 10 years. After five years the diagnoses were re-evaluated by three of the study 
clinicians based on all available data at the time [141] where the focus was on 
participants with “possible” AD/DLB/VaD diagnoses, or an unexpected clinical 
course.  
A total of 46 brain autopsies with neuropathological analysis had been performed at 
the time of publication of paper I, supporting the clinical diagnosis of AD and LBD in 
approximately 85% of the patients. The accuracy of the diagnostic procedure has later 
been evaluated in 56 participants with neuropathological diagnosis, with a sensitivity 
and specificity for probable DLB of 73 % and 93 % respectively, and a sensitivity 
and specificity of 80 % and 92 % for AD [239].  
Magnetic resonance Imaging and white matter hyperintensities 
A structural MRI was performed in participants with no contraindication for this 
examination (otherwise a CT scan was performed) at three different sites (Stavanger 
University Hospital (Stavanger), Haugesund Hospital (Haugesund) and Haraldsplass 
Deaconess Hospital (Bergen)). In all three centres a 1.5 T scanner was used. (Philips 
Intera in Stavanger and Haugesund and a 1.5T GE Signa Excite scanner in Bergen). 
The assessment of WMH were done volumetrically as previously described [240]. In 
addition WMH load was rated visually according to the Scheltens scale [240, 241]. 
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Assessment of vascular risk factors  
Assessment of vascular risk factors were done based on patient history and 
medication use. The following vascular risk factors were included: smoking, 
overweight, hypertension, hypercholesterolemia, and diabetes mellitus. Participants 
who reported smoking at baseline were defined as smokers while those who had 
never smoked or had quit smoking were defined as non-smokers. Having a BMI ≥ 
25kg/m2 was defined as being overweight. Hypertension, hypercholesterolemia, and 
diabetes mellitus were defined as follows: 
Hypertension: having a previous diagnosis of hypertension or being treated with 
antihypertensive drugs (i.e., beta-blockers, diuretics, Angiotensin-converting-enzyme 
inhibitors, calcium-antagonists or angiotensin receptor antagonists).  
Hypercholesterolemia: having hypercholesterolemia reported in the medical history 
or using a statin.  
Diabetes mellitus: having diabetes mellitus reported in the medical history, or usage 
of insulin or oral antidiabetic drugs (i.e., sulfonylureas, biguanides, glinides, alpha-
glucosidase inhibitors, thiazolidinediones, DPP-4 inhibitors and GLP-1 analogues).  
A combined total vascular risk factor summation score was created by adding the 
scores of the different vascular risk factors, giving a score from 0 (no vascular risk 
factors) to 5 (having all the vascular risk factors). 
3.3.2 Dementia Disease Initiation 
At baseline the participants underwent a comprehensive clinical evaluation including 
a full medical history from both the participant and informant, physical and 
neurological examinations in addition to blood tests including APOE genotyping, 
MRI scan of the brain and lumbar puncture for CSF Aβ42 analyses [210]. 
Blood samples were drawn by standard routine at each centre. Blood samples were 
immediately centrifuged and plasma and serum were aliquoted before freezing at -80 
degrees Celsius, and subsequently collected and stored at the main study centre 
AHUS. Serum lipid analyses done locally at every centre included total cholesterol, 
HDL-cholesterol, LDL-cholesterol and triglycerides. However LDL-cholesterol 
analyses were not done at 2 centres. EDTA blood was used for lipid profiling 
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analyses, and was centrifuged at 1200 g for 13 min before plasma were aliquoted in 
polypropylene tubes and stored at -80°C. Time from venepuncture until aliquoted 
plasma was frozen was below 2 hours. Plasma was kept at -80°C until analysis. 
Plasma lipid profiling was performed at King’s College London, UK, using methods 
described previously [242, 243] and extensively described in paper II. 
Lumbar puncture 
The lumbar puncture procedure was performed before noon. The CSF was collected 
in Polypropylene tubes (Thermo Nunc) and centrifuged within 4 hours at 2000g for 
10 minutes in room temperature. The supernatant was then transferred to new tubes 
and frozen at -80ºC. All CSF analyses were performed at the Department of 
Interdisciplinary Laboratory Medicine and Medical Biochemistry at Akershus 
University Hospital (AHUS). CSF from other sites was frozen at respective sites 
before sending to the analysing laboratory. ELISA (Innotest β-Amyloid (1–42), 
Innotest h-Tau Ag and Innotest Phospho-Tau (181P), Fujirebio, Ghent, Belgium) was 
used to determine CSF Aβ42, total tau, and phosphorylated tau. The CSF Aβ42 
measurements were dichotomized using a threshold of 708 ng/mL, with values below 
the threshold defined as positive [244].  
APOE genotyping  
APOE genotyping was performed on EDTA blood samples either at AHUS (Gene 
Technology Division, Department of Interdisciplinary Laboratory Medicine and 
Medical Biochemistry) according to the laboratory’s routine protocol using real-time 
PCR combined with a TaqMan assay (Applied Biosystems, Thermo Fisher Scientific, 
Waltham, USA) or at the University Hospital of Trondheim according to the protocol 
for the Fast Start DNA Master HybProbe Kit (Roche, Basel, Switzerland) in 
combination with the LightMix ApoE C112R R158C kit from TiB MolBiol (Berlin, 
Germany) followed by LightCycler technology (Roche, Basel, Switzerland). 
Cognitive battery and MCI diagnosis 
The cognitive examination included the MMSE [211], verbal learning and memory 
(CERAD word list test) [221], visuoperceptual ability (VOSP silhouettes) [228], 
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psychomotor speed (TMT-A), divided attention (TMT-B) [231] and verbal fluency 
(COWAT) [229]. Standardised T-scores (M=50, SD=10) were calculated for the tests 
based on demographically adjusted norms [223, 228, 230] except for the MMSE test. 
The cognitive assessment is performed approximately every 2 years. Research staff 
participates in bi-annual meetings, with case discussions to align procedures. A 
memory composite score was constructed and adjusted for age, sex and education as 
described in section 2.1.1 
In order to diagnose MCI, the NIA-AA criteria were used, requiring reporting of 
subjective cognitive decline, verified objectively by lower performance on clinical 
cognitive tests in one or more cognitive domains [58, 62]. Originally, as described by 
Fladby et al. [210], the cutoff value for MCI (defined as normal versus abnormal 
cognition) was based on scores ≤ 1.5 SD below normative means on either CERAD 
word list (delayed recall) [221], VOSP silhouettes [228], TMT-B [231] or COWAT 
[229], or having an MMSE [211] score ≤ 27. Later, in 2019 MCI was defined as 
results ≤ 1.5 SD below the age, sex and education adjusted normative mean on either 
CERAD word list (delayed recall) [223], TMT-B, COWAT [230] or VOSP 
silhouettes (this test was adjusted for age only) [228]. After a thorough review of the 
literature, the DDI steering group found that the use of the MMSE as a MCI criterion 
could produce an elevated rate of false positive MCI diagnoses, and was thus 
excluded from the diagnostic algorithm.  
More details of recruitment and diagnostic procedures have been described 
previously [210]. The participants of the DDI study are being examined biannually 
until they are diagnosed with dementia, after which they are excluded from the study. 
Currently the participants are mainly undergoing 2 – and 4 year follow-up 
assessments using same protocol as baseline. 
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3.3.3 Anthocyanin study 
At inclusion, all participants in the anthocyanin group underwent a physical 
examination, including standardised blood pressure measurement, electrocardiogram 
(ECG), and blood tests. In addition a cognitive test battery was administered. 
Cognitive functions were assessed by MMSE [211] and verbal memory function was 
assessed using the Norwegian adaptation of the Ten Word List Learning and Recall 
from the CERAD battery [220]. TMT A and B [231] and Stroop Golden test [235] 
were used to assess executive functioning. The GDS-15 was used to ensure that none 
of the participants had depression. 
Following standardised procedures, participants provided blood samples in the 
morning after having been fasting for at least 8 hours, at baseline and after 16 weeks 
of anthocyanin supplementation. The blood samples were immediately centrifuged 
and plasma and serum were aliquoted before freezing at -80 ºC. Markers of 
inflammation were analysed after completion of the study by The Lipid Research 
Group, Department of Clinical Sciences, University of Bergen, in Bergen, Norway. 
After completion of the study, anthocyanin metabolites were measured in plasma at 
Department of Nutritional Sciences, School of Life Course Sciences, Faculty of 
Medicine and Life Sciences, King’s College London, using a method based on 
microelution solid phase extraction followed by liquid chromatography and mass 
spectrometry, using authentic standards, as previously described, with some 
modifications [245]. Further details regarding the blood tests can be found in paper 
III [3].  
The normal control group provided blood samples for analysis but was not given 
anthocyanin supplementation and did not complete the cognitive test battery. 
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Anthocyanin study design 
 
 
Figure 1: Overview of design of the Anthocyanin study 
HbA1c = glycosylated haemoglobin. CERAD = The Consortium to Establish a Registry for Alzheimer’s 
disease word-list learning and memory test. TMT = Trail Making Test. 
In an open label design, the participants in the anthocyanin group were given 
anthocyanin supplementation for 16 weeks. The anthocyanin containing product used 
was Medox® capsules, a standardised nutraceutical product that contains naturally 
purified anthocyanins from bilberry (Vaccinium myrtillus) and black currant (Ribes 
nigrum). The content of each capsule is: Maltodextrin Glucidex IT 19, Bilberry 
(Vaccinium myrtillus) and Black Currant (Ribes nigrum) extract powder with 80 mg 
anthocyanin citrates as the 3-O-rutinosides of Cyanidin and Delphinidin and the 3-O-
b-galactopyranosides, 3-O-b-glucopyranosides and 3-O-a-arabinopyranosides of 
Cyanidin, Peonidin, Delphinidin, Petunidin and Malvidintha [246]. The production of 
Medox® capsules has been described previously [247]. Each capsule contains 80 mg 
anthocyanins, and the participants were given the capsules at inclusion of the study, 
and were instructed to consume two capsules twice daily for a total daily intake of 
320 mg anthocyanins for 16 weeks. The rationale for choosing this dosage was that it 
has previously been reported to be safe in use [248], and also to have biological 
effects [23, 248, 249]. 
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The participants were asked to maintain their dietary and lifestyle habits during the 
study period. Further, the participants were asked explicitly during and after the study 
period whether they had been taking anthocyanin capsules as instructed, and were 
reminded of the importance of keeping the empty blister packages. Protocol 
adherence was assessed by collecting and counting the empty blister packages and 
left-over capsules at study end. 
Blood tests taken for safety reasons included haemoglobin, thrombocytes, kidney 
function and liver function tests, which were measured at both baseline and study-
end. All participants were contacted by telephone at week 8 in order to get 
information regarding potential side-effects and adverse events (AE). 
 Statistical analyses 
Unless otherwise stated, the statistical data were analysed using the most recent 
version available of IBM® SPSS® Statistics for Windows. 
In order to check the assumptions of normality of continuous variables, the 
Kolmogorov-Smirnov and the Shapiro-Wilk tests were used in addition to inspection 
of QQ-plots and histograms. When in doubt, the total number of subjects was taken 
into account and normality plots were discussed with a statistician. 
Descriptive statistics were presented as means and standard deviations (SD) or 
medians and interquartile ranges (IQR) for symmetrical and non-symmetrical 
continuous variables respectively, and as counts and percentages for categorical 
variables.  
For all statistical analyses p < 0.05 was considered statistically significant except for 
analysis done in paper II as described below. 
In paper I, Generalised Estimating Equations (GEE) was used to explore potential 
associations between baseline vascular risk factors and longitudinal outcome data, 
while adjusting for age, sex, all other vascular risk factors, and time since baseline. 
GEE takes into account the correlation between multiple visits per subject through a 
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so-called working correlation matrix. Confidence intervals for association measures 
are based on robust (sandwich) estimates of standard errors. To assess whether a 
baseline group variable was associated with the slope of change of the outcome, the 
model included group and time main effects, and a group x time interaction effect.  
The Spearman rho correlation was used in order to assess the associations of the 
different vascular risk factor scores and the Scheltens total score and CSF Aβ42. 
 In paper II multiple groups were compared. Between-group comparisons were done 
using one-way ANOVA for continuous variables with normal distributions, with 
Welch correction for heteroscedasticity/unequal variances. The Kruskal-Wallis tests 
for the continuous variables of non-normal distributions. For statistically significant 
ANOVA, post-hoc Bonferroni (equal variances assumed) or Tamhane’s T2 (equal 
variances not assumed) analyses were performed as applicable by Levene’s test. For 
Kruskal-Wallis tests Bonferroni adjusted Dunn’s pairwise comparisons were applied. 
The regression analyses were done using RStudio (1.2.1335). Logistic regression was 
applied to assess whether there was an association of plasma lipids with diagnosis at 
baseline. Linear regression analyses were applied to assess the association of plasma 
lipids with primary or secondary neuropsychological tests at baseline and the change 
in them between baseline and follow-up.  
In order to calculate the change in cognitive outcomes between baseline and follow-
up, each cognitive test at follow-up was regressed against the baseline and the 
residuals were used (further adjusted for months of follow-up). 
For all regression analyses a stepwise adjustment model was used. Potential 
confounders included in the models were BMI, hypercholesterolemia, hypertension 
and smoking status. In addition, age, sex and education were included in the logistic 
models. Adjustments for age, sex and education were not done the in linear 
regression models as the derived T-scores were previously adjusted for these 
variables. Subsequently both the linear and logistic regression analyses were adjusted 
for APOE status. As 70 is the number of lipid principal components explaining >95% 
 59 
of variation in the 261 identified lipids following principal component analysis, a 
Bonferroni threshold of p<0.0007 (0.05/70) was used.  
As the number of variables exceeds that of the observations (p>n) and as lipids are 
highly correlated, multivariate analysis such as Partial least squares discriminant 
analysis (PLS-DA) and Random Forests (RA), were performed on the main 
outcomes. This was done in order to observe whether associations between the lipids 
and the tested outcomes remained when taking into account lipids’ intercorrelation, 
and to identify which lipids and combinations of lipids are strong contributors to the 
outcomes.  
In paper III between-groups comparisons were performed by the Independent-
samples t-test, the Mann-Whitney test or Chi-square test as applicable upon 
comparing two independent groups. Within-group analyses were done by the 
Wilcoxon Signed Rank test or the paired samples t-test applying the Welch correction 
in situations with heteroscedasticity/unequal variances when applicable. 
 Ethical considerations 
All the three studies were approved by the regional committee for medical and health 
research ethics (REK), specifically in western Norway (REK 2010/633) for the 
DemVest study, and in southeast for the DDI study (REK 2013/150) and the pilot 
study (REK 2014/1966). The Anthocyanin study was registered at Clin.Gov.Trial 
(NCT02409446). All the data obtained from all three studies are kept in accordance 
with the Norwegian recommendations on data privacy.  
The participants gave their written informed consent before taking part in any of the 
studies, and all participants were considered to have capacity to consent on their own 
behalf. In addition, in the DemVest study a carer, usually the spouse or an offspring, 
also signed informed consent. In addition to participate in the clinical part of the 
study, all patients of DemVest were asked to consent for post mortem brain autopsy.  
After the Anthocyanin study had started, the research group was made aware of a 
theoretical possibility that anthocyanins might increase the risk of bleeding [250]. 
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Although the study group was not aware of systematic evidence supporting this 
claim, treatment with Warfarin, heparin or non-vitamin K antagonist oral 
anticoagulants was added as exclusion criteria. All participants were informed by 
letter about this potential issue, and given the opportunity to withdraw from the study. 
The REK was informed of this matter and approved the changes and let the study 
continue. 
 
The Anthocynin study was financed in part by a grant from Sandnes Sparebank, 
Sandnes, Norway given to Biosynth AS to support the study. Medpalett AS, Sandnes, 
Norway contributed to the study by producing Medox® free of charge. Neither 
Sandnes Sparebank, Biosynth AS nor Medpalett AS had any influence on the design 
or conduction of the study, the analyses and interpretation of data, or regarding the 
decision to publish the findings. 
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4. Results 
 Paper l 
A total of 200 patients with mild dementia were included (AD n=113, LBD n=87 
(DLB n=69, PDD n=18)). Except for sex distribution, there were no significant 
differences between the AD and LBD groups when comparing the demographical 
data. The mean follow-up time was 3.5 years, and there was at least one follow-up 
assessment for 186 patients (107 AD and 79 LBD). For all patients the mean annual 
decline in MMSE scores was 2.6 and the annual decline was found to be 2.7 in the 
AD group, and 2.3 in the LBD group.  
Regarding the vascular risk factors in the total sample, a total of 53% had 
hypertension, 9% diabetes mellitus, 25% had hypercholesterolemia, 40% were 
defined as being overweight (BMI ≥ 25), and 19 % were current smokers.  
 
For both dementia groups being overweight at baseline was associated with a slower 
decline in MMSE scores (p < 0.001) and a slower increase in CDR-SB scores (p < 
0.001). Smoking was associated with a more rapid increase in CDR-SB scores in the 
AD group (p = 0.045), and with a slower decline in MMSE in the LBD group (p = 
0.045). In the LBD group, diabetes mellitus was found to be associated with a slower 
increase in CDR-SB scores (p = 0.047), and hypertension with a slower decline in 
MMSE (p = 0.043). Hypertension was associated with an increase in MMSE in the 
total group (p=0.033). In the subgroup of patients with APOE genotyping, adjustment 
for APOE status had no noticeable effect on the results. 
The vascular risk factor summation score was significantly associated with a slower 
decline in cognitive function as measured by MMSE, however the results for CDR-
SB were inconsistent. 
WMH were associated with hypertension (r = 0.27, p = 0.007), but there were no 
significant associations with other vascular risk factors. Further no significant 
associations were found between CSF Aβ42 and any of the vascular risk factors. 
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 Paper II 
A total of 149 age and sex matched subjects took part in the study, where 3 groups 
were defined; MCI Aβ+ (N=50), MCI Aβ- (N=49) and normal controls (N=50). 
There were a few (1-5) missings on cognitive tests, but 138 participants had complete 
follow-up cognitive assessment after an average of 24.5 months. Regarding 
education, medical history, smoking status, BMI and serum lipid status the groups 
were equal, but as expected the groups differed in the cognitive test results. Most 
lipids were found to be inter-correlated and associated with many of the covariates 
(age, sex, education, BMI, serum lipid status, diabetes mellitus, 
hypercholesterolemia, hypertension, lipid lowering medication, smoking status and 
APOE status).  
In this exploratory study a total of 261 plasma lipids were identified and further 
annotated in 8 groups as ceramides, diacylglycerols, phosphatidylcholines, 
Lysophosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols, 
sphingomyelins or triglycerides.  
Only one sphingomyelins (SM(d43:2)) was associated with MCI Aβ+ compared to 
controls after passing correction for multiple testing, being decreased in MCI Aβ+ 
(OR=0.29, 95% CI 0.14-0.56, p=6.2 x10-4). Further, SM(d43:2) was found to be 
associated with MCI Aβ+ compared to MCI Aβ-, being nominally reduced in MCI 
Aβ+ individuals, at p<0.05 (OR=0.52, 95% CI 0.29-0.89, p=2.1 x10-2).  
In the primary neuropsychological test analyses, no associations with CERAD 
composite T-score at baseline or the change in CERAD composite T-scores between 
baseline and follow-up passed correction for multiple testing. 
In the secondary analyses, two associations passed correction for multiple testing; 
two phosphatidylinositols (PI(38:3) and PI(38:4)) were associated with baseline 
VOSP T-score, i.e. increase in two phosphatidylinositols was associated with 
decrease in VOSP at baseline after correction for multiple testing (beta=-3.98, 95% 
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CI -6.0 – -2.00 p=1.12 x10-4 and beta=-3.65, 95% CI -5.59 – -1.71, p p=2.89 x10-4 
respectively). 
 
Multivariate data analysis was also performed, finding that the lipids with the highest 
variable importance (VIP) in most models were the same lipids that were highlighted 




Among the 33 participants included in the study who started anthocyanin 
supplementation, 27 (8 MCI and 19 non-obstructive coronary artery disease) 
completed the study. A total of 6 participants were excluded for not being compliant 
with the study protocol as one participant had an exclusion criterion, two participants 
were not able to attend follow-up as scheduled, and three participants did not ingest 
the anthocyanin capsules according to protocol. In addition 20 normal controls were 
included in the plasma analyses, but did not receive any intervention. 
Interleukin 8 (IL-8), MCP-1, CCL-5/“regulated on activation, normal T-cell 
expressed and secreted” (RANTES) and TNF-α, were available for statistical 
analyses. The other inflammation markers did not reach measurement thresholds. 
Regarding the between-group analyses, the only statistically significant difference 
were for ΔMCP-1 (difference from baseline to study end) (p=0.011) and Δfasting 
glucose (p=0.003). 
In the within-group analyses of the anthocyanin supplementation group, statistically 
significant increases were found in total cholesterol (p=0.009) and triglycerides 
(p=0.016) from baseline to study end. In the normal control group statistically 
significant changes were found for MCP-1, which increased from baseline to study- 
end (p=0.014). Although no statistically significant changes were found for fasting 
glucose and HbA1c in the anthocyanin group, in the normal control group there was a 
statistically significant decrease in fasting glucose (p=0.009) from baseline to study 
end. 
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In the intervention group the cognitive test scores improved for CERAD learning 
(p=0.016), recall (p < 0.001) and recognition (p=0.05) and for Stroop Golden test 
word (p < 0.001) and colour (p = 0.044). 
In plasma a total of 29 anthocyanin metabolites were quantified. Between-group 
analyses found a statistically significant difference for two metabolites (o-Coumaric 
acid (p=0.019) and Dihydroferulic acid-4-O-Sulfate (p=0.010)), which both had a 
larger decrease in the anthocyanin group than in the normal control group. Overall the 
within-group analyses of the anthocyanin metabolites were inconsistent by showing a 
statistically significant increase in five of the metabolites and a statistically 
significant decrease in five other metabolites in the anthocyanin group. Further, the 
within-group analyses of the normal control group showed a statistically significant 
decrease in four metabolites but no statistically significant increases in any of the 
metabolites from baseline to study end. 
Regarding compliance, more than 85% of the participants returned at least 90% of the 
expected empty blister packages. The participants reported tolerating the 
anthocyanins well, and importantly, none of the participants withdrew due to adverse 
effects. Further, none of the participants chose to withdraw from the study after 
receiving the information letter regarding the theoretically increased risk of bleeding. 
Blood tests taken for safety reasons were all within a clinically acceptable range. 
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5. Discussion 
In the present thesis the overall aim was to investigate the potential implications of 
vascular risk factors and lipid alterations for development and progression of 
cognitive impairment, and the possible effect of anthocyanin supplementation in a 
population of people with mild dementia or at increased risk of dementia. Herein the 
potential effects of vascular risk factors on the progression of AD and LBD were 
investigated in paper I. Further, paper II explored the plasma lipid profile in mild 
cognitive impairment due to AD and its association with cognition, while paper III 
explored the effect of anthocyanin supplementation in adults and older people with 
increased risk of dementia.  
This section will be a discussion of the results in the three papers of the thesis. The 
findings will be compared to those of previous studies, where both similarities and 
inconsistencies will be discussed. In addition, a critical assessment of the 
methodology applied and its possible influence on the results will be provided. 
 Paper I 
5.1.1 Vascular risk factors and progression of Alzheimer’s Disease 
and Lewy body dementia 
The potential effect of vascular risk factors on the progression of mild AD dementia 
and LBD was studied in paper I. Contrary to the hypothesis, with the exception of 
smoking, no vascular risk factors were associated with a faster cognitive decline in 
people with mild dementia due to AD or with mild LBD. 
In the AD patients, an association of smoking at the time of dementia diagnosis with 
a more rapid cognitive decline was found when using CDR-SB as outcome measure. 
Smoking cessation is a relatively manageable modifiable risk factor found to be 
beneficial even in older persons [9]. Even so, the finding however, is not in line 
compared with both previous studies as shown in Table 1 and later research reporting 
no association of smoking and AD dementia progression [30, 251, 252]. In the LBD 
group however, smoking was associated with slower cognitive decline when MMSE 
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was used as outcome measure which is somewhat in line with later findings of slower 
cognitive decline in DLB being associated with recent or present smoking [252]. 
Interestingly, the latter study also found an association of smoking and slower 
progression of frontotemporal dementia [252]. 
A key finding in paper I was that at the time of dementia diagnosis, being overweight 
was associated with a slower progression of cognitive decline in both AD and LBD 
patients. This is in contradiction to previously published studies laid out in Table 1, as 
none of the studies reported an association of being overweight and a slower decline 
of cognitive impairment in patients with dementia. In paper I it was found that 40 % 
of the participants were overweight (defined as BMI >25). This is in line with the 
findings in a Norwegian study of AD patients with MCI or dementia diagnosis at 
baseline reporting 41.4 % of the participants to be overweight [251]. This 2-year 
follow-up study reported only a trend for patients with high BMI to progress less than 
patients of normal weight [251]. Irimata et al. analysed the effect of BMI on different 
types of dementia progression and did not find an association of BMI and cognitive 
decline in AD or DLB, but an association was found between higher BMI and slower 
frontotemporal dementia progression [252].  
The association of being overweight at the time of dementia diagnosis with a slower 
progression of cognitive decline in both AD and LBD might be seen as an aspect of 
what has been referred to as the “obesity paradox”; while mid-life obesity is related to 
higher dementia risk, higher BMI after age 65 is inversely related to dementia risk 
[108]. Interestingly, a study has shown that weight loss negatively confounds the 
deleterious effect of adiposity in the brain structure in elderly and might explain the 
“obesity paradox” on AD risk [253]. Further, a recent study found higher late-life 
BMI to be associated with lower levels of CSF AD biomarkers, higher brain volumes, 
and slower cognitive decline [254].  
The association of hypertension and hypercholesterolemia with dementia progression 
has in several previous studies been inconsistent, as shown in Table 1. In paper I, no 
association was found for hypercholesterolemia with progression of AD and LBD. 
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Although some studies have shown no effect on dementia progression, most studies 
have reported hypertension to be associated with more rapid dementia progression, 
which is somewhat contradictory to the findings of paper I where hypertension was 
found to be associated with a slower cognitive decline in the total group when MMSE 
was used as the outcome measure and a slower cognitive decline in the LBD when 
CDR-SB was used as the outcome measure. Later, Irimata et al. have reported recent 
or active hypertension and hypercholesterolemia to be the two most frequently co-
occurring vascular risk factors at baseline and to be associated with slower cognitive 
decline in AD patients [252].  
Of note, extensive WMH have been associated with dementia and hypertension [255, 
256]. Further, in paper I a significant relationship between hypertension and WMH 
was found. The lack of an association between hypertension and cognitive decline 
might suggest that cerebrovascular pathology, as reflected in WMH load is not an 
important contributor to cognitive decline after onset of neurodegenerative dementia. 
This might also be a possible explanation as to why a relationship between diabetes 
mellitus and a slower increase in CDR-SB scores in LBD patients was found. That is; 
once a patient is diagnosed with a neurodegenerative disease, the disease will 
progress independently of vascular risk factors, including diabetes mellitus. However, 
there could be alternative explanations, as discussed below. 
The vascular risk factor summation score was significantly associated with a slower 
decline in cognitive function as measured by MMSE, however the results regarding 
CDR-SB were inconsistent. Both previous studies (as shown in Table 1) and later 
studies have reported discrepancy regarding multiple vascular risk factors or 
increased vascular burden and progression of dementia. A Norwegian study with 2-
year follow-up observed a trend of slower disease progression in the patients with 
three or more vascular risk factors, however increased vascular burden assessed by 
the Framingham Stroke Risk Profile had no association with AD dementia 
progression [252]. However, a Taiwanese study including AD dementia patients with 
annual follow-up for 3 years concluded that multiple vascular risk factors have 
summative effects leading to faster progression of AD, especially in APOE ε4 carriers 
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[257]. The discrepancies between the studies might have multiple explanations. Not 
only do they differ in selection criteria for their participants and methodology, they 
also differ in how increased vascular burden is assessed. In general, some studies use 
the number of vascular risk factors in an additive manner to assess vascular burden, 
while others use different scores allowing for differentiated weighting of individual 
risk factors.  
The literature shows that the relationship between vascular risk factors and dementia 
progression is still unclear [30, 252]. Since the association of mid-life vascular risk 
factors and late-life dementia has been well-established in previous epidemiological 
studies, the discrepancy, and often lacking association of late-life vascular risk factors 
and dementia progression is somewhat surprising. There could be a number of 
reasons for these discrepancies. The comparability of the studies is limited, due to 
differences in outcome measurements as different cognitive tests to assess decline in 
cognition were used, and also different statistical analyses. Of note, for some studies 
it is unclear which statistical analyses they have employed, and although adjustments 
of the multivariate analyses were mostly similar, some studies adjusted for more 
factors than others. The follow-up time also varied between the studies. Furthermore, 
some studies only looked at one type of dementia while others analysed different 
dementia types. The way in which patients were recruited and selection criteria also 
differed. Although some studies are population based, most were based on cohort of 
memory or outpatient clinics.  
Regarding the vascular risk factors, there is no standardised way on how they should 
be defined or measured in order to study their potential impact on dementia 
progression. Treatment of the vascular risk factors might influence the results of 
different studies but information regarding this is seldom available. In addition, the 
reporting of anti-dementia medication is also highly variable [30]. Further, as several 
vascular risk factors tend to decrease in the years leading up to dementia [109, 115, 
258], using the evaluation of only current levels of risk factors without taking into 
account previous risk might influence the results. In addition, the effect of vascular 
risk factors or their treatment might differ between men and women but studies have 
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usually not been reported separate analyses per vascular risk factor by gender. Lastly, 
as suggested above, in individuals with dementia due to AD or LBD, the brain might 
already be so compromised by neuropathology that any impact of vascular risk 
factors does not have additional effect on cognitive functioning. 
5.1.2 Study sample 
The participants of paper I were drawn from the DemVest study. In line with the 
Norwegian health care system, most mild dementia cases are diagnosed and followed 
by general practitioners, however in the DemVest study all general practitioners, and 
all neurology clinics in the region of south-western Norway (Rogaland and 
Hordaland) were informed of the study, and invited to refer their patients to one of 
the participating outpatients clinic for evaluation and inclusion in the study. Hence, 
the sample in DemVest is a referral-based sample, the participants of the study may 
thus not be representative of the total dementia population, which might have 
implications for the generalizability of the results of study. Also after 2007 DLB and 
PPD participants were recruited selectively and are thus relatively overrepresented in 
the total sample which therefore may not necessarily be representative of the general 
dementia population. However the relative overrepresentation of the LBD would 
likely not influence the findings in the AD and LBD groups separately. 
As the recruitment took place in outpatient clinics, one could possibly expect an 
overrepresentation of participants with comorbidities, which could possibly have 
influenced the results in paper I. Even so, the vascular comorbidity was comparable 
with that of another Norwegian study examining the effect of vascular risk factors on 
AD progression [251]. 
The DemVest study has been ongoing since 2005, making it a study with a long 
follow-up time compared to most other studies. Importantly, except for death, the 
study has low attrition, and from the total of 266 patients who underwent baseline 
assessment, only 24 (9.0%) patients have withdrawn during the study period. Further, 
the majority of the patients have been followed until death with repeated 
measurements using standardised and structured instruments at annual follow-up 
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times, allowing for persistent and repeated analyses in patients progressing from mild 
to severe dementia. 
5.1.3 Dementia diagnosis 
Patients screened for inclusion in the DemVest study underwent a comprehensive 
baseline assessment integrated into clinical practice using standardised clinical 
instruments and diagnostic criteria. Now after 15 years the DemVest study is still 
ongoing during which time there have been changes in diagnostic criteria, and 
increased use of supplementary diagnostic and biomarkers in clinical practice. Both 2 
and 5 years into the study the diagnostic criteria were re-applied, providing a high 
standard of diagnostic precision [141]. Neuropathological diagnosis has also been 
provided, showing a good agreement between clinical and neuropathological 
diagnosis, although both false negative and false positive diagnoses occur. 
Specifically, regarding a clinical diagnosis of probable AD, the sensitivity, 
specificity, positive predictive value and negative predictive values were 81%, 88%, 
89%, and 79%, respectively, while out of 20 patients with neuropathologically 
verified LBD, 16 had a clinical diagnosis of LBD (DLB=11, PDD=5), resulting in a 
sensitivity, specificity, positive predictive value and negative predictive value of 
80%, 92%, 84%, and 89%, respectively [239]. In paper I the diagnoses from the 2 and 
5 year evaluations were used, including the available neuropathological diagnoses 
(N=46), giving a high likelihood of correct diagnoses. 
In order to increase power in the analyses of paper I, patients with DLB and PDD 
were combined in one LBD group. This is considered justified as they are both α-
synucleinopathies and share a number of clinical and pathological similarities [38]. 
Further, naturalistic longitudinal data from Sweden found DLB and PDD to be 
similar synucleinopathies, with phenotypical variations in the order of manifestations 
(as expected) rather than course of progression and clinical outcome [259]. 
5.1.4 Clinical assessment 
Study participation was integrated in the clinical practice and many clinicians took 
part in the multicentre design of DemVest. However, this could increase the risk of 
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both systematic errors, and possible random errors which could decrease the 
reliability of the findings. 
Time of onset of risk factors is of great interest as middle age onset versus elderly 
onset and treatment of vascular risk factors could possibly affect the progression of 
AD. Per design of the DemVest study, patients were included at time of dementia 
diagnosis, and accordingly, information regarding previous diseases are retrospective 
and subject to recall bias by the patient and caregiver, and thus detailed information 
regarding the age at onset of diseases could not be recorded. Further, limitations to 
the vascular risk factors assessments of the DemVest study include the lack of some 
serological data, possibly introducing some bias. Most probably due to glycosylated 
haemoglobin (HbA1c) not being among the routine measurements at memory 
outpatient clinics at the time of study inclusion, only 24 patients among the 200 
patients of Paper I had available measures of HbA1c, potentially resulting in 
underestimation of patients having diabetes mellitus as a vascular risk factor.  
Hypercholesterolemia was defined as having hypercholesterolemia in the medical 
history and or being a statin user, without taking into account the measured level of 
serum cholesterol levels at baseline. This was done do to missing (n=41 missings) of 
this measure and the fact that the patients had not been fasting in advance of the test. 
Hence, patients registered as having hypercholesterolemia were all statin users which 
could possibly lead to misclassified data as the statin medication could have been 
prescribed for another reason than hypercholesterolemia, e.g. secondary prevention 
after cerebral and/or cardiac event. Also, patients with hypercholesterolemia might 
have been missed as the blood tests were not evaluated for high levels of cholesterol 
which could be due to hypercholesterolemia. 
5.1.5 Main outcome measures 
The main outcome, and also measure of AD and LBD progression were MMSE and 
CDR which have been previously described in section 3.2.  
MMSE is well known, both in clinical and research settings [214, 215]. The 
limitations however, include practice effects and the relatively limited number of 
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cognitive domains assessed. As changes in function and behavior are not assessed, 
cognitive tests alone would likely not capture all changes in AD dementia and LBD. 
Further, the MMSE may be less sensitive in measuring change in LBD patients, 
possibly due to the MMSE not directly assessing psychiatric, autonomic, or executive 
functions often impaired in patients with DLB [260, 261]. 
The CDR-SB captures a broader assessment of cognitive and daily functioning and is 
thus potentially a more accurate and comprehensive measure of dementia severity in 
patients with LBD. Still, it was originally designed for use in patients diagnosed with 
AD dementia, and is not adequately tested in DLB [141, 217]. Further, it is more time 
consuming, and requires information from a next of kin. 
5.1.6 Statistical considerations 
In the main analyses of paper I, Generalized Estimating Equations (GEE) with 
unstructured working correlation was used to explore the association between 
vascular risk factors and cognitive decline in patients with AD and LBD.  
The association analyses were adjusted for age and gender, but should preferably also 
have been adjusted for education, as education might influence the result on MMSE 
[214]. Further, the vascular risk factors were dichotomized, as in many other studies. 
This could potentially reduce the statistical power, thus limiting the chances of 
identifying associations between vascular risk factors and the progression of 
dementia. Further, this may also reduce the ability of making comparisons with other 
studies with different cut-off values for different vascular risk factors. 
An unexpected finding was that AD patients were predicted to have a steeper 
cognitive decline than LBD patients. This is different from a previous paper [141] 
based on DemVest data reporting that cognitive decline is more rapid in DLB than in 
AD. The discrepancy in these findings are probably due to the different statistical 
methods applied which deals with drop-outs due to death differently. There were 20 
patients (12 AD, 8 LBD) who withdrew or were lost to follow-up, and 93 (36 AD, 57 
LBD) dropouts due to death. The statistical analyses have therefore later been 
reconsidered. Raitanen et al. [262] studies three options to deal with dropout due to 
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death, each of which will produce results with different interpretations. Briefly, 1) 
GEE (with independent working correlation) estimates the average level of 
functioning among those still under study at each time point, i.e. will give an estimate 
of how functioning develops among completers/survivors; 2) linear mixed models 
(LME) treat death as any other random drop-out and implicitly assumes that the 
subject-specific trajectories extend after death, leading to results interpretable as the 
expected development if death did not exist; whereas 3) joint modelling of 
longitudinal outcome and survival times corrects the possibly deviating development 
leading up to death to give estimates that can be interpreted as the expected 
development if no one had died.  
Unpublished results using method 1) described above are similar to our published 
results with regard to the associations of vascular risk factors and progression of 
decline. Hence, the results of paper I can be interpreted as associations among 
survivors. Of note, some of the published findings in paper I were changed when 
using the other methods described by Raitanen et al. With these methods, as 
expected, the progression of cognitive decline was more consistent with previous 
reports. The findings reported in paper I should therefore be interpreted with some 
caution. 
 Paper II 
5.2.1 Lipid alterations in Alzheimer’s Disease  
The main finding in paper II was somewhat in line with the hypothesis as lower 
plasma sphingomyelin concentrations, and in particular SM(d43:2), were found to be 
associated with AD pathology. However, no plasma lipids were associated with 
performance on primary neuropsychological tests at baseline or between baseline and 
follow-up. In the secondary outcomes, two phosphatidylinositols were found to be 
negatively associated with visuospatial functioning at baseline. 
Previous studies have shown alterations in the sphingomyelin pathways in AD [32, 
130]. A study using plasma shotgun lipidomics reported decreased sphingomyelin 
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and increased ceramide levels in plasma of AD patients as compared to controls 
[263]. This finding is supported by targeted sphingolipidomics studies that identified 
similar sphingolipid changes in plasma of patients with MCI [264, 265], and AD 
[266]. Further, a recent study using untargeted metabolomics profile analyses 
adjusting for APOE status, and ethnic/racial group reported significant differences 
comparing exogenous and endogenous metabolites in patients with AD and healthy 
controls and confirmed previous findings in sphingolipid metabolism pathways [267]. 
Of note, the finding of paper II is not in agreement with all previous studies as a small 
cross-sectional study reported lower levels of plasma sphingomyelin in AD patients 
compared to controls [135].  
Plausible explanations to the conflicting results between different studies could 
possibly be, the stage of the AD may have an effect on the level on sphingomyelin 
measured. Mielke et al. reported that the levels of serum sphingomyelin vary 
according to the timing of the onset of memory impairment, a deficit observed early 
in AD pathogenesis [264]. Of note, age, sex and APOE status have been reported to 
have an effect on sphingomyelin metabolism, but this has not been assessed properly 
in all previous studies [268, 269]. Interlaboratory variability and methodology have 
been observed across studies. Various studies report the use of blood samples from 
participants who were fasting, while in other studies the participants were non-fasting 
at the time of blood withdrawal. Also the use of serum versus plasma and how blood 
products are processed varies between studies. This might affect the results, further 
underlining the importance of consistency across different studies and laboratories 
[32]. It should be noted that the provenance of SM(d43:2) is not clear. In humans, 
sphingomyelin levels across bio-fluids are largely regulated by multiple signaling 
pathways and are dependent on the contribution from diet but also de novo synthesis, 
recycling, and intestinal uptake. However SM(d43:2) has been detected in previous 
lipidomics validation studies [243].  
The relationship between sphingolipid changes and cognitive impairment in AD has 
also been studied in brain tissue and CSF [32, 126]. Sphingomyelin has been found to 
be elevated in CSF in AD patients [131, 132] and studies on brain tissue have shown 
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alterations in lipid profiles and disturbed ceramide metabolism in AD [129]. Kosicek 
et al. found significantly increased sphingomyelin levels in CSF from individuals 
with prodromal AD compared to normal controls, however no change between mild 
and moderate AD groups and normal controls [131].  
The research showing an association between sphingolipid metabolism and AD is 
intriguing. However, the exact biochemical mechanism(s) leading to the reduction of 
these peripheral blood lipids in people with AD is unknown. Further, the relation 
between systemic abnormalities and the pathogenesis of AD is poorly understood. 
Varma et al. designed a study in order to link alterations in metabolite signals in the 
brain to those in the blood, and found that higher blood concentrations of 
sphingolipid species were consistently associated with severity of AD pathology at 
autopsy and AD progression across prodromal and preclinical stages [128]. However, 
it is still uncertain if sphingolipid misbalance is a consequence of Aβ accumulation or 
one of the initiating factors of AD pathophysiology [130]. Interestingly, ceramides 
have not only been reported to be associated with cerebral Aβ levels, but are also 
intermediates linking inflammatory cytokines to insulin resistance and diabetes 
mellitus, and contribute to cardiovascular disease and obesity, all of which are 
associated with AD [270, 271].  
In paper II no association between sphingomyelin, or any other lipid, and the 
progression of cognitive decline was found. Previous longitudinal studies that 
monitored the progression of cognitive decline in AD patients reported elevated 
plasma ceramide and low sphingomyelin to predict faster cognitive decline [136, 
137]. Reason for not finding an association between plasma sphingomyelin and 
cognitive decline in our study could be the relatively low number of participants in 
and the relatively short study duration.  
In the secondary outcomes of paper II, two phosphatidylinositols were found to be 
negatively associated with VOSP T score, suggesting that an increase in the 
phosphoinositols was associated with reduced performance on visuospatial 
functioning at baseline. Phosphatidylinositols belongs to the phospholipids which are 
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structurally and biologically membrane-forming lipids influencing many complex cell 
processes including modulation of membrane proteins and their functions [122].  
Although phospholipid changes have been reported in previous studies to occur 
during the pathogenetic process in AD, different phospholipid species have been 
found to be altered [122, 133, 272].  
Interestingly, Mapstone et al. [273] reported a panel of ten serum lipids to predict 
MCI or dementia where one of the lipids was a phosphatidylinositol [273]. These 
results were not be replicated in later studies possibly explained by different 
methodology [274, 275]. Also, a recent study examined whether phosphoinositols, 
and metabolites would change in erythrocytes of AD and amnestic MCI patients 
compared to normal controls [276]. The study found decreased levels of 
phosphatidylinositol in erythrocytes of amnestic MCI patients, a finding that indicates 
that disturbed levels of phosphatidylinositols in erythrocytes occur in the early stage 
of AD, possibly in the prodromal phase, but no phosphatidylinositol differences were 
found between amnestic MCI and AD groups, indicating that the expression of 
phosphatidylinositols in erythrocytes may not reflect the severity of AD [276]. These 
findings require verification in larger well-designed studies of longer duration. 
5.2.2 Study sample 
For paper II the participants were drawn from the DDI cohort, which includes 
participants with subjective cognitive impairment, MCI and normal controls. 
Altogether 150 participants were selected by manual matching. Later, one participant 
was excluded due to change in the diagnosis from MCI to subjective cognitive 
impairment after the introduction of new demographic adjusted criteria [223]. 
The group sample sizes are relatively small with 49 in MCIAβ- and 50 in the Aβ+, 
and normal control groups. The samples in the different groups were sex and age 
matched, and 2 year follow-up was available for most participants.  
Of note, the participants in the DDI study were included from university hospitals in 
the four Norwegian health regions (Helse Sør-Øst, Helse Midt, Helse Nord and Helse 
 77 
Vest) from general practitioners referrals. In addition recruitment was also done by 
self-referral following advertisements in media, newspapers or news bulletins. An 
important issue is that due to geographic differences in Norway, the availability of 
memory clinics may differ possibly leading to a biased inclusion of memory clinic 
referrals living in, or near city centers where the university hospitals are located. This 
might lead to reduced generalizability of the findings of paper II. 
5.2.3 MCI-AD diagnosis 
The participants were examined following the comprehensive DDI assessment 
protocol. By the use of published criteria, the participants were staged as either 
healthy controls, or having subjective cognitive decline [57] or MCI [58, 62]. An 
important finding by the DDI research group is that use of the Sotaniemi et al. [222] 
CERAD WLT normative dataset may be unfit for the DDI cohort as these norms are 
based on a sample that is on average 10 years older and less educated than the DDI 
cohort, possibly resulting in an uncertain classification of MCI and subjective 
cognitive decline [277]. This finding ultimately led to the development of new 
demographic adjusted regression-based norms for the CERAD word list (delayed 
recall) [223], and the use of it and other demographic adjusted tests; TMT-B, 
COWAT [230] or VOSP silhouettes (this test was adjusted for age only) [228].  
Participants were included in the DDI in the prodromal phases and MCI stage of AD, 
which provides an optimal design to capture early stages of AD and follow disease 
development through a longitudinal study. An advantage of the sample of paper II 
was that the AD pathology was ensured by CSF biomarkers [244]. 
5.2.4 CERAD composite score  
In paper II the CERAD composite score was used as a measure of cognitive decline. 
This score was constructed as described in section 3.2. Further standardised T-scores 
were then calculated and used as main outcome measure. The intention of 
constructing the CERAD composite was to have a more robust and reliable test of 
learning and memory function including being more robust against chance low 
performance on one measure not related to neurodegeneration or cerebral dysfunction 
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(e.g. low motivation or inattention during a particular test). However, the use of a 
CERAD composite could be a limitation, as this could possibly mask domain specific 
cognitive functions such as learning, recall and recognition, which are qualitatively 
different aspects of learning and memory. Hence, two of the subdomain measures of 
the CERAD WLT (learning and delayed recall) as well as other cognitive domains 
(psychomotor speed, executive functions, verbal fluency/language, and visual 
cognition) were used in the secondary analyses. 
5.2.5 Statistical considerations 
A possible statistical concern when analysing large numbers of variables is the risk of 
making type 1 errors, i.e. falsely rejecting the true null-hypothesis. However, in order 
reduce the risk of incorrect conclusions, post-hoc analyses as well as stringent 
correction for multiple testing were done in the statistical analyses of paper II. 
Logistic and linear regression analyses were used controlling for a number of 
variables associated with lipids and cognitive decline including age, sex, education, 
BMI, lipid lowering medication, smoking status, and history of hypercholesterolemia 
and hypertension.  
A further strength is that a machine learning approach using Partial least squares-
discriminant analysis (PLS-DA) and Random Forest (RF) was used for the main 
outcomes, and the results from the two approaches are in agreement. 
 Paper III 
5.3.1 Effect of anthocyanins on dementia relevant mechanisms 
In paper III, contrary to the hypothesis, the results were largely inconclusive with 
regard to the potential protective effects of anthocyanin supplementation. 
Significant increases in serum levels of total cholesterol and triglycerides, but no 
significant change in LDL- and HDL-cholesterol were observed in the anthocyanin 
group. There were no significant changes in the lipid profile of the normal control 
group. The findings of the Anthocyanin study differ from several previous studies 
which have reported anthocyanins to improve the blood lipid profile in middle-aged 
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dyslipidemic participants, possibly through reverse cholesterol transport [248, 249, 
278]. A systematic review and meta-analysis reported anthocyanin supplementation 
to reduce serum total cholesterol, triglycerides, and LDL-cholesterol but to increase 
HDL-cholesterol compared with controls who were given placebo. Importantly, these 
findings were based on studies including middle aged participants with dyslipidemia 
[21]. There are several limitations to the published studies as the sample sizes and the 
study durations are rather short. Studies are from rather few countries and involve 
participants in the middle-age group, many having comorbidities and treatment 
affecting serum lipids as exclusion criteria [21, 23, 248, 249, 278-280]. Hence, the 
results are often applicable to certain populations, and can not necessarily be 
generalized to other populations and age groups. Even so, a British study of a 
somewhat older population (age 63 ± 7 years) with metabolic syndrome reported an 
increased HDL-cholesterol concentration after six months of treatment with 
anthocyanins from 3 types of intervention foods (equivalent to 1 and 1/2 US cup 
blueberries, and placebo), especially in statin non-users, but there were no changes in 
total cholesterol, LDL-cholesterol or triglycerides [198].  
The discrepancies in the findings between the Anthocyanin study and other studies 
could have a number of explanations related to differences in participants, as well as 
to anthocyanin supplementation dose and study duration, or other factors. The 
nutraceutical Medox® used for the anthocyanin supply in the Anthocyanin study has 
been used in previous studies showing a statistically significant increase in HDL-
cholesterol [23, 247-249, 278, 279] and a decrease in LDL-cholesterol [23, 248]. 
Importantly, while these mentioned studies included dyslipidemic and 
hypercholesterolemic participants were the use of any drugs known to affect lipid 
metabolism were exclusion criteria [23, 248], altogether 70% of the participants in 
the Anthocyanin study were taking statins or other lipid lowering medication. 
The Anthocyanin study did not find any significant changes in serum levels of fasting 
glucose and HbA1c in the anthocyanin group. However, a statistically significant 
lower fasting glucose was found in the normal control group. In comparison, an 
Australian study were a total of 55 participants in two groups of normal healthy and 
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metabolic syndrome (age 25-75 years) were given a daily dose of 320 mg 
anthocyanin supplementation 4 weeks reported significant reduction in in the serum 
fasting glucose in the metabolic group [281]. Meta-analysis assessing glycemic 
regulation in both healthy population and those with cardiometabolic disease found 
that anthocyanins significantly reduced fasting glucose, as well as two hour 
postprandial glucose, and HbA1c [19]. Further, several meta-analyses of 
epidemiologic research suggest anthocyanins to have a dose-dependent role in 
diabetes mellitus type 2 risk reduction, but the exact mechanisms explaining this 
potential association are not clear [20, 282]. A proposed mechanism for diabetes 
mellitus type 2 risk reduction is that antocyanins decrease insulin resistance [20]. 
However, these studies have had small sample size and short duration, and not always 
found decreased insulin resistance [283-286]. A recent randomized controlled trial of 
six months duration did not find any change in insulin resistance after treatment with 
anthocyanins [198]. More prospective studies in different regions and ethnic groups 
are warranted. 
In the Anthocyanin study IL-8, MCP-1, RANTES and TNF-α, were available for 
statistical analyses. These are pro-inflammatory mediators involved in systemic 
inflammation of both metabolic syndrome and atherosclerosis, and in 
neuroinflammation [287-290]. Of note, the presence of systemic inflammation with 
increased TNF-α production is associated with increased cognitive decline, glial cells 
activation, and neuroinflammation [287]. RANTES decreased, however not 
significantly in the anthocyanin supplementation group and increased not 
significantly in the normal control group, however the between-group analysis 
showed no significant differences. Another Norwegian study of healthy adults 
showed that 3-week intake of purified anthocyanins decreased plasma IL-8 and 
RANTES. That study did not however result in significant alterations in C reactive 
protein (CRP), TNF-α and IL-1β levels [291]. Further, in a randomized, double-blind 
clinical trial, 24 weeks of anthocyanin supplementation versus placebo consumption 
in 150 hypercholesterolaemic individuals found significantly reduced plasma levels 
of RANTES as compared with the placebo [292]. Another study found however no 
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effect on inflammatory biomarkers, including TNF-α and RANTES following 12 
weeks of consumption of anthocyanin extract in healthy postmenopausal women 
[293]. 
Possibly the efficacy of anthocyanin on inflammatory responses depends on the 
studied populations, the duration of the intervention and also the dose and type of 
anthocyanin source and how it is prepared. A recent meta-analysis indicated that 
dietary anthocyanins significantly decreased levels of CRP, IL-6, TNF-α, intercellular 
adhesion molecule-1, and vascular adhesion molecule-1 (VCAM-1) in dose 
dependent manner [294]. Supplementation with anthocyanins may modulate the 
inflammation processes and further research of anthocyanin supplementation as a 
potential strategy in prevention and treatment of inflammatory diseases is warranted 
[295].  
In the secondary analyses, significant improvements in the CERAD learning, recall 
and recognition scores and Stroop Golden test word and color were found. The 
findings are in line with previous smaller studies involving participants with MCI, 
reporting improved cognition after ingestion of anthocyanins [202, 203]. Further, 
randomized, double-blinded, placebo-controlled studies have reported improved 
episodic memory and cognition after 3 months of anthocyanin supplementation [205, 
296]. Of note, although the results of a recent review provide preliminary evidence 
for the potential efficacy of anthocyanins as an intervention to promote cognitive 
performance and mood, there is only a limited number of trials, with heterogeneous 
age groups, large variation in cognitive tests between trials, relatively small sample 
sizes, and differing anthocyanin content in the interventions. Thus, further 
investigations are needed, including the use of a well-defined standardised 
anthocyanin supplement [297].  
Importantly, variations in type and dose of anthocyanins, the source of anthocyanins, 
preparation, and also the storage of the food containing the anthocyanins will affect 
the amount of anthocyanin actually being administered. As the anthocyanin 
composition can vary depending on the food source or whether they are fresh, frozen 
or dried, well-defined means of anthocyanin supplement is of importance [298]. 
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The results of the 29 anthocyanin metabolite analyses in plasma were conflicting as 
various anthocyanin metabolites were found to be increased or decreased in the 
anthocyanin group. These results are possibly explained by high inter-individual 
variability and the influence of the background diet, and are in line with a previous 
study [245]. Interestingly, previous studies have shown anthocyanin-derived 
metabolites to correlate with biological effects including improvements in vascular 
function [22, 196]. A recent study however observed that cognitive benefits were 
correlated with parent anthocyanin compounds suggesting the possibility that 
recurrent intake of anthocyanins, rather than metabolites, was related to the cognitive 
benefit [299]. 
Currently, the evidence for anthocyanin supplementation for cognitive improvement 
is inconclusive, mainly due to the insufficiencies and discrepancies in the study 
designs and also lack of biological and physical endpoints [18]. It has previously been 
recommended that future studies should utilize pure anthocyanins in well-designed 
long-term, properly controlled and blinded trials assessing physiologic endpoints 
before drawing conclusions regarding their specific biological function on 
cardiovascular risk factors and cognitive function [18]. Importantly, although some 
studies of shorter duration exist [22, 300-302], longer-duration trials on dose-
response effects and possible risk of long-term ingestion are needed. Therefore, based 
on the experience from the Anthocyanin study, our research group has been 
conducting a phase II randomized controlled trial examining the effect of purified 
anthocyanins in people at risk of dementia over 6 months including a comprehensive 
biomarker collection [246]. 
5.3.2 Study sample and design 
The sample of paper III was subjects participating in the Anthocyanin study. 
Participants were recruited from both the outpatient Memory and Cardiology clinics 
at the Stavanger University Hospital, of whom a majority were recruited from the 
cardiologic outpatient clinic. In line with the Norwegian health care system 
recommendations, most patients with MCI are being diagnosed and treated in the 
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primary health care system. Participants of the DDI study [210] in Stavanger with a 
diagnosis of MCI were also invited to participate. 
The Anthocyanin study has several limitations including the non-randomized open-
label design, the small sample size, and the relatively short intervention period. 
Except for age and sex, there is no knowledge about the normal control group. 
At the time when the Anthocyanin study was designed, the planning of a larger 
randomized controlled trial also started, and the decision was made to implement a 
pilot study to gain experience concerning recruitment, feasibility and safety. This was 
also in accordance with the decision from the the regional committee for medical and 
health research ethics (REK) 
 The Anthocyanin study was a pilot study with the aim of generating hypotheses and 
facilitating design and power calculations for future randomized trials rather than 
aiming at providing firm conclusions. A more sophisticated and robust design is 
required to increase the understanding of the effects of anthocyanins that may 
possibly benefit the aging brain and mechanisms leading to dementia. Also, valuable 
feedback from participants can be used in further facilitating recruitment in larger 
studies. 
Of note, a well characterised combination of nutraceuticals was used, the contents of 
which has been described in section 3.3.3. This facilitates comparison with other 
studies. This particular nutraceutical capsule has also been used in previous clinical 
studies, but this is the first time it is used in a study examining cognitive function.  
A limitation of the study was the lack of registration of the diet or other lifestyle 
measures of the participants, and thus differences in the background diet and other 
lifestyle factors may have influenced the findings. However, participants were asked 
to maintain their lifestyle during the intervention period. Reported data are prone to 
bias, and biological measurements of anthocyanin metabolites, which were measured, 
are of preference.  
 84
Since the study period was relatively short, with 16 weeks between the two test 
points, the cognitive tests results may have been prone to learning effects.  
5.3.3 MCI diagnosis 
Participants in the MCI group had been diagnosed with MCI before inclusion. Those 
recruited by the DDI study had been diagnosed according to the original criteria in 
the DDI Study [210] as described in section 3.3.2, whereas those recruited by the 
Memory outpatient clinic had been diagnosed by a trained physicians following 
standardised clinical evaluation. We cannot fully exclude that this might have 
influenced the findings, but this is unlikely. 
The distinction between MCI and mild dementia is not always clear. The intention 
was to include mild dementia in the pilot study, however no participant had mild 
dementia. Possibly this was because of the exclusion criterion of MMSE score < 24, 
and most patients with mild dementia probably had a MMSE score < 24.  
5.3.4 Statistical considerations 
The sample of paper III was small, involving only 27 participants in the anthocyanin 
group and 20 normal controls. Thus there is a clear risk of both type I errors, i.e. 
assuming there is a difference between the groups, but there really is not, and type II 
errors, i.e. assuming there is no difference between the groups when there really is a 
difference. Non-parametric analyses were chosen as the most suitable due to the 
small sample size and to avoid having to rely on assumptions of symmetrically 
distributed data. However, descriptive statistics including variance measurements 
were provided, which may be helpful in planning later studies, including facilitating 
design and power calculations. The presented data may also be eligible for inclusion 






The general aim of this thesis was to increase knowledge about the role of vascular 
risk factors, lipid alterations and anthocyanin supplementation with respect to 
development and progression of cognitive impairment in a population of people with 
mild dementia or at increased risk of dementia. 
This thesis is based on three published papers, which together provide interesting 
findings about vascular risk factors and mechanisms underlying cognitive impairment 
and dementia, and concerning the potential to intervene in order to delay or prevent 
the progression of cognitive decline. The main findings and conclusions from the 




The main findings in paper I were that smoking was the only vascular risk factor 
significantly associated with a more rapid cognitive decline in AD patients, and that 
being overweight at the time of dementia diagnosis was associated with a slower 




The main finding in paper II was that plasma sphingomyelins, and in particular 
SM(d43:2), were reduced in patients with MCI due to AD pathology compared to 
controls, and were also nominally reduced when compared to MCI patients without 
AD pathology. In addition, two phosphatidylinositols were found to be negatively 




In paper III the findings are somewhat inconclusive. The only significant between- 
group difference was with respect to the within-group difference of MCP-1 and 
fasting glucose (difference from baseline to study end). In the anthocyanin group, 
total cholesterol and triglycerides increased, but there were no significant changes in 
serum levels of fasting glucose, HbA1c or markers of inflammation. Some cognitive 
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improvements were observed in the anthocyanin group. Anthocyanin 
supplementation was well tolerated, without any recorded adverse events, and the 
compliance was good. 
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7. Implications and further research 
The number of people with cognitive impairment and dementia is increasing both 
worldwide and in Norway leading to substantial impact on the individuals, their 
families and societies. AD and LBD are the most common neurodegenerative causes 
of dementia, with AD being the most common cause of dementia overall. As there are 
currently no available disease-modifying treatments, measures to reduce risk of 
developing cognitive impairment and dementia, as well as measures to decrease 
disease progression are crucial.  
The main aim of this thesis was to increase the knowledge about the potential effects 
of vascular risk factors, lipid alterations and anthocyanin supplementation on 
development and progression of cognitive impairment. This might have some 
implications as will be discussed below, and suggestions for further research will be 
provided. 
 Vascular risk factors and dementia progression 
Although the association of mid-life vascular risk factors with increased risk of late-
life dementia has been well established, the association of late-life vascular risk 
factors and dementia progression is still not clear. Vascular risk factors are potentially 
manageable, and a delay in the progression of dementia could benefit even the oldest 
old. Fewer years of life being dependent on full-time care, or in nursing home would 
be beneficial also with respect to carer burden and health care costs. However, based 
on research findings to date, it is still questionable whether intensive treatment of 
vascular risk factors, considering potential side-effects of medication use, and 
potentially polypharmacy, would benefit the older patients diagnosed with dementia. 
Also, little knowledge exists regarding the effect of vascular risk factors on other 
causes of dementia than AD. Hence, further studies are needed to explore the 
associations of vascular risk factors with cognitive decline, and how this could be 
translated into benefit for people with dementia. Future studies should be done in 
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well-defined longitudinal cohort studies using standardised diagnostic tools, and 
biological biomarkers for different dementia subtypes. 
 Lipid alterations in Alzheimer’s Disease 
The exact cause and pathomechanism of AD is not known, and research has until 
recently been focused on protein- and gene-centric causes. However, lipid alterations 
have in several studies been associated with AD pathology, and present a role not 
only in AD pathomechanism but possibly also as a biomarker for disease and 
progression, and as a treatment target. Hence, additional knowledge and 
understanding of the possible contribution of lipids to AD pathology is of interest. 
Future studies should preferably link blood based lipidomics changes with 
neuropathology and integrate findings with known genomic and proteomic alterations 
of AD pathology. 
It is not known whether the observed changes in lipid levels associated with AD 
pathology are causally related to, or are just a marker of changes, and therefore 
studies that address potential causality are essential. Future analyses should use larger 
sample sizes to replicate already existing findings. Additionally, longer follow-up 
time might give a better picture of how lipids might affect changes in cognitive 
outcomes. Analysis consistency across laboratories is important to establish in order 
to be able to replicate findings.  
Of importance, proteins and genes are known to be affected in AD and can function 
complementarily with lipids, f.ex. in lipid rafts. Hence, lipidomics experiments 
should not detract from investigations of proteomics and genomics. Lipidomics 
presents a novel and unique platform to analyse AD processes and biomarkers, but 
changes in lipids should preferably be evaluated in the context of gene and protein 
changes in order to give a more holistic picture of AD processes. 
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 Effect of anthocyanin supplementation on dementia 
relevant mechanisms 
At best, the effect of anthocyanin supplementation on dementia relevant mechanisms 
and cognitive function is encouraging. In view of the public health burden associated 
with neurodegeneration, in particular AD, safe, low-cost dietary interventions offer 
the possibility of inducing substantial benefit. 
Findings from observational, preclinical, and smaller clinical studies need to be 
substantiated by both well designed and well defined randomized controlled trials. 
Importantly, studies will require the use of well defined, and hence comparable and 
repeatable sources of anthocyanins.  
Future studies should assess cognitive function in a standardised manner, using the 
latest guidelines for diagnosis and should also include standardised acquisition of 
biomarkers, both structural and functional neuroimaging, as well as analyses of 
biofluids such as CSF. The intervention period needs to be long, preferably 12-24 
months [18]. Genetics should be employed in order to explore whether or not there 
are differential responses to dietary anthocyanin supplementation in specific APOE 
genotype carriers. 
In addition to further research on the potential effects of anthocyanins in terms of 
counteracting cardiovascular and metabolic risk factors, inflammation, oxidation and 
associated neurodegenerative disease, studies on intervention doses will be of 
importance. Although some have already been published, further confirmatory 
studies will be needed.  
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Background: Anthocyanins may protect against cardiovascular related cognitive
decline and dementia.
Objective: Open-label study to measure changes in serum lipids, glucose, glycosylated
hemoglobin (HbA1c), and markers of inflammation after anthocyanin supplementation
in people with increased risk of dementia. As a secondary endpoint we examined
potential changes in a battery of cognitive test in the anthocyanin group (AG). A total
of 27 individuals with mild cognitive impairment (MCI) (n = 8) or stable non-obstructive
coronary artery disease (CAD) (n = 19) consumed two Medox R© capsules, each
containing 80 mg of natural purified anthocyanins, twice daily for 16 weeks. They
provided blood samples and performed a short battery of cognitive tests. Twenty
healthy normal controls (NC) (n = 20) provided blood samples, but did not receive any
intervention and did not perform cognitive tests.
Results: There was a significant difference between groups for CCL-5/RANTES
[regulated on activation, normal T-cell expressed and secreted (RANTES)]. In addition,
total cholesterol and triglycerides were significantly increased in the AG. Improvements
in memory and executive test scores were observed. No adverse effects were reported.
Conclusion: The results of this pilot study were largely inconclusive with regard
to the potential protective effects of anthocyanin supplementation. However,
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anthocyanins were well tolerated, and compliance was high. Larger, placebo-
controlled studies to explore the potential effects of anthocyanins on dementia risk
are encouraged.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT02409446.
Keywords: mild cognitive impairment, MCI, anthocyanins, lipids, inflammation markers
INTRODUCTION
Anthocyanins, a subclass of the flavonoids, are found in foods
such as berries and fruits and information regarding their content
in food can be found in an online phenol-explorer (Neveu et al.,
2010). Anthocyanins have been shown in previous studies to
have a number of positive health effects, such as improving the
blood lipid profile (Qin et al., 2009; Li et al., 2015), and also
fasting serum glucose and glycosylated hemoglobin (HbA1c) in
diabetic patients (Li et al., 2015; Yang et al., 2017), and have
anti-inflammatory effects (Xia et al., 2007; Spencer et al., 2012;
Spagnuolo et al., 2017). Anthocyanins can improve endothelial
and vascular function (Rodriguez-Mateos et al., 2013, 2016,
2019), and can cross the blood–brain barrier (Faria et al., 2014)
and thus may reduce neurodegenerative and cerebrovascular
changes and possibly protect against cognitive decline and
dementia. Interestingly, some studies have found that food-
based anthocyanins can improve memory functioning in older
adults with mild cognitive impairment (MCI; Krikorian et al.,
2010a,b; Hein et al., 2019). However, these studies were based on
relatively small samples, and had a short duration. In addition,
food-based anthocyanin supplementation leads to heterogeneity,
i.e., variations in types of food sources, concentration, and dose
of anthocyanins.
In this exploratory open-label pilot study, we aimed
as a primary endpoint to examine potential changes in
dementia-relevant mechanisms after 16 weeks of treatment
with purified anthocyanin containing capsules, in people with
increased risk of dementia. As a secondary endpoint we also
explored the potential change in a battery of cognitive tests.
MATERIALS AND METHODS
Material
Participants were recruited from the outpatient Memory and
Cardiology clinics at Stavanger University Hospital in Norway
during 2015 and 2016. Eligible for this study were patients
with MCI or mild dementia and/or stable non-obstructive
coronary artery disease (CAD). Potential participants identified
at the respective outpatient clinics were contacted for a
telephone interview by a study doctor, regarding inclusion
and exclusion criteria. Participants were also recruited from
the dementia disease initiation (DDI) study (Fladby et al.,
2017). Inclusion criteria were age ≥50 years and being
on stable medication, including nutraceuticals for the past
3 months, and either (a) confirmed CAD without physiologically
significant stenosis evaluated by coronary angiography, or
(b) having MCI or mild dementia according to ICD 10
(World Health Organization [WHO], 1992).
Exclusion criteria were moderate to severe dementia
[operationalized as a mini-mental status exam (MMSE) (Folstein
et al., 1975) score < 24], clinically significant depression [15–item
Geriatric Depression Scale (GDS-15) (Mitchell et al., 2010)
score ≥ 7], unstable CAD, heart failure in need of treatment,
having taken Medox R© during the past 3 months, using Warfarin,
heparin or non-vitamin K antagonist oral anticoagulants
(NOAC), inflammatory illnesses such as rheumatoid arthritis
and other severe illness with <5 years expected survival. Any
treatment with vitamins, minerals or nutraceuticals had to
have remained stable for the last 3 months prior to inclusion
and during the study. Healthy normal controls (NC) (n = 20)
recruited from the staff at Stavanger University Hospital and
through acquaintances, were ≥50 years, had stable medication,
and had not been taking Medox R© for the last 3 months. This
group provided blood samples at inclusion and 16 weeks later,
but did not take Medox R© or other interventions, and did not
perform the cognitive test battery. The rationale for including
this comparison group was to have a reference group with
respect to any observed changes in the blood analyses in the
intervention group.
Ethics Statement
All participants provided written informed consent, and the
study has been approved by the Regional Ethics Committee
(Approval 2014/1966). The study has been registered at
ClinicalTrials.gov (NCT02409446).
Intervention, Design, and Assessment
Intervention
The participants were given open-label Medox R© capsules,
provided free of charge by the manufacturer Medpalett AS,
Sandnes, Norway. Medox R© capsules, which contain specific
quantities of natural purified anthocyanins from bilberry
(Vaccinium myrtillus) and blackcurrant (Ribes nigrum), have
been used previously in human studies (Karlsen et al., 2007).
The production of the Medox R© capsule (Hassellund et al.,
2013), and its anthocyanin content (Qin et al., 2009) have been
described previously.
The capsules were dispensed at inclusion in the study,
and the participants were instructed to consume two 80 mg
anthocyanin capsules twice daily for a total daily intake of 320 mg
anthocyanins for 16 weeks. This dosage was chosen because it has
previously been shown to have biological effects (Qin et al., 2009;
Zhu et al., 2011; Li et al., 2015) and found to be safe in use (Qin
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et al., 2009). A review found that doses up to 640 mg/day showed
no adverse events (Wallace et al., 2016).
Participants were instructed to maintain their dietary and
lifestyle habits in order to avoid interferences in the study results.
Design and Assessment
At inclusion, all participants underwent a physical examination,
including standardized blood pressure measurement,
electrocardiogram (ECG), and blood tests. In addition a
cognitive test battery (see below) was administered, including
the MMSE and GDS-15. Following standardized procedures,
participants provided blood samples in the morning after
having been fasting for at least 8 h, before and after 16 weeks
of treatment. They were contacted by telephone after 8 weeks
regarding safety and compliance.
Blood Sampling and Analyses
Blood was collected, centrifugated, and stored at −80 ◦C
until analysis according to standardized procedures. The serum
samples were analyzed for lipids (total cholesterol, triglycerides,
HDL- and LDL cholesterol) and fasting glucose using Architect
c16000 TM (Abbott Diagnostics, Chicago, IL, United States)
and HbA1c using Variant II turbo (BioRad, Hercules, CA,
United States) at Stavanger University Hospital.
Markers of inflammation were analyzed after completion
of the study by The Lipid Research Group, Department
of Clinical Sciences, University of Bergen, Bergen, Norway.
Concentrations of cytokines were measured in serum using
the Bio-Plex ProTM Human Cytokine 8-plex assay (Cat.:
M50000007A) which included GM-CSF, IFN-γ, IL-2, IL-4, IL-6,
IL-8, IL-10, and TNF-α, in addition to five Bio-Plex Pro Human
Cytokine single-plexes: MCP-1 (Cat.: 171B5021M), RANTES
(Cat.: 171B5025M), G-CSF (Cat.: 171B5017M), IL-17 (Cat.:
171B5014M), and IL-Iβ (Cat.:171B5001M). All plexes were
manufactured by Bio-Rad (Hercules, CA, United States). The
cytokines were detected by the Bio-PlexTM 200 System and
determined with the Bio-Plex Manager Software 6.1. The samples
were prepared as described in the protocol (Cat.: 10014905) with
a dilution factor of three.
Anthocyanin metabolites were measured in plasma after
completion of the study at Department of Nutritional Sciences,
School of Life Course Sciences, Faculty of Medicine and
Life Sciences, King’s College London, using a method based
on microelution solid phase extraction followed by liquid
chromatography and mass spectrometry, using authentic
standards, as previously described with some modifications
(Feliciano et al., 2016). The detection of plasma (poly)phenol
metabolites was performed on a ExactiveTM Orbitrap Mass
Spectrometer (Thermo Scientific, Waltham, CA, United States)
after separation on an Accela 1250 pump UHPLC system
(Thermo Scientific, Waltham, CA, United States). The
autosampler injected 5 µL of each sample in a Zorbax Eclipse
Plus RRHD column 2.1 mm × 50 mm, 1.8 m with a compatible
Eclipse Plus guardcolumn 2.1 mm × 5 mm, 1.8 m (Agilent,
Waldbronn, Germany). The mobile phase consisted of 0.1%
HCOOH (solvent A) and acetonitrile with 0.1% HCOOH
(solvent B) in a 10 min gradient program. Quantification
analysis of the plasma (poly)phenols was done using Xcalibur 2.2
(Thermo Scientific, Waltham, CA, United States).
Cognitive Tests
Verbal memory function was assessed using the Norwegian
adaptation of the Ten Word List Learning and Recall from
the CERAD battery (Morris et al., 1989), a three part test;
word list learning, word list delayed recall, and word list
delayed recognition.
Executive functioning was assessed by the Trail Making Test
(TMT) A and B (Reitan and Wolfson, 1985) and Stroop Golden
(Golden, 1976). The Trail Making Tests A and B are tests of
psychomotor speed and attention shifting (Ashendorf et al.,
2008), while Stroop Golden is a test used to evaluate cognitive
speed and inhibition (Scarpina and Tagini, 2017).
Safety
Participants were contacted by phone at week 8 to ask about
potential side-effects and adverse events (AE).
The safety blood tests included hemoglobin, thrombocytes,
kidney function and liver function tests, which were measured
at both baseline and study-end.
Compliance
Participants were contacted by phone at week 8 and asked
about adherence to the protocol. Specifically, they were asked
whether they had been taking Medox R© capsules as instructed, and
they were reminded about keeping the empty blister packages.
Protocol adherence was also assessed by collecting and counting
the empty blister packages and left-over capsules at study-end.
Statistical Analyses
Descriptive statistics are presented as medians and interquartile
ranges (IQR), and illustrated using Box plots. Most data were
not normally distributed and thus the main analyses were
non-parametric. The Mann–Whitney U test and the Chi-square
test were used for between-group comparisons. Changes from
baseline to follow-up at 24 weeks within groups were analyzed
with the Wilcoxon Signed Rank test. For all tests p ≤ 0.05 was
considered statistically significant.
Supplementary parametric analyses were performed, from
which we present means, standard deviations (SD), and p-values
from paired and independent samples t-tests.
The IBM SPSS statistical package version 24 was used for all
statistical analyses.
RESULTS
During the period May 2015 to September 2016, 33 participants
started anthocyanin supplementation, of whom 27 (8 MCI and 19
CAD) completed the study (6 were excluded for administrative
and logistical reasons) (Figure 1). The NC were included in the
period December 2016 to February 2017. No subjects with mild
dementia were included.
Baseline characteristics are shown in Table 1.
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FIGURE 1 | Enrolment of participants. N, number.
TABLE 1 | Baseline characteristics.
Active (n = 27) Controls (n = 20)
Median (IQR) Median (IQR)
Women, count (%) 9 (33) 11 (55)
Age (years) 61 (55− 70) 58 (55− 62)
CAD, count (%) 19 (70)
Education (years) 11.5 (10− 14)
BMI 27.7 (26.0− 30.3)
Lipid lowering therapy, count (%) 19 (70)




Dietary supplement, count (%) 18 (67)
CAD, coronary artery disease; BMI, body mass index; IQR, interquartile range.
Only IL-8, MCP-1, CCL-5/RANTES [regulated on activation,
normal T-cell expressed and secreted (RANTES)] and TNF
were available for statistical analyses, as the other inflammation
markers did not reach measurement thresholds. The findings are
summarized in Table 2 and Supplementary Figures S1–S3.
The only significant between-group difference was for
1RANTES (difference from baseline to study end) which
decreased in the supplementation group and increased in the NC
group (Table 2).
When analyzing the groups separately, significant increases
were found in total cholesterol and triglycerides in the
anthocyanin supplementation group (AG) from baseline to
study end (Table 2), and MCP-1 which increased in the NC
group (Table 2).
No significant changes were found for fasting glucose and
HbA1c in the AG group.
A total of 29 plasma anthocyanin metabolites were quantified
(Table 3 and Supplementary Figure S4). When comparing the
two groups, a statistically significant difference was found for
two metabolites (o-Coumaric acid and Dihydroferulic acid-4-O-
Sulfate), which both had a larger decrease in the AG than in the
NC group (Table 3).
In the AG, there was a statistically significant increase in
five of the metabolites (Pyrogallol-2-O-sulfate, Protocatechuic
acid-3-O-sulfate, Pyrogallol-1-O-sulfate, Ferulic acid-4-O-
β-D-glucuronide, Isoferulic_acid-3-O-β-D-glucuronide)
and a statistically significant decrease in five other
metabolites (3-Hydroxyhippuric acid, 4-Hydroxybenzaldehyde,
Dihydroferulic acid-4-O-Sulfate, m-Coumaric acid, o-Coumaric
acid) after 16 weeks of anthocyanin consumption in
comparison with baseline.
In the NC group, there was a statistically significant
decrease in four metabolites (Protocatechuic acid, 3,4-
Dihydroxyphenylacetic acid, 4-Hydroxybenzaldehyde and
o-Coumaric acid), whereas there were no statistically significant
increases in any of the metabolites.
The cognitive test scores improved in the intervention group,
with improvements for CERAD learning (p = 0.016), recall
(p < 0.001) and recognition (p = 0.047) and for STROOP
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TABLE 2 | Changes from baseline to 16 weeks follow-up in serum variables, for participants with supplementation (active) and for control participants.
Active (n = 27) Control (n = 20) Active vs. control
Median (IQR) p∗ Median (IQR) p∗ p#
Cholesterol (mmol/L) Cholesterol
Pre 4.0 (3.1 to 5.5) 5.1 (4.5 to 5.5)
Post 4.6 (3.3 to 6.0) 5.1 (4.6 to 5.6)
Diff 0.2 (0.1 to 0.7) 0.009 0.1 (− 0.2 to 0.5) 0.29 0.34
HDL (mmol/L) HDL
Pre 1.2 (1.0 to 1.4) 1.5 (1.1 to 1.7)
Post 1.2 (1.1 to 1.5) 1.4 (1.2 to 1.8)
Diff 0.0 (− 0.1 to 0.1) 0.81 0.1 (− 0.1 to 0.1) 0.21 0.23
LDL (mmol/L) LDLn = 19
Pre 2.4 (1.8 to 3.9) 3.3 (2.9 to 3.9)
Post 3.0 (1.8 to 4.3) 3.3 (2.8 to 4.0)
Diff 0.1 (− 0.1 to 0.3) 0.21 0.0 (− 0.1 to 0.4) 0.62 0.72
Triglycerides (mmol/L) Triglycerides
Pre 1.0 (0.7 to 1.4) 0.9 (0.6 to 1.3)
Post 1.0 (0.7 to 1.7) 0.9 (0.6 to 1.8)
Diff 0.1 (0.7 to 1.7) 0.016 0.0 (− 0.1 to 0.4) 0.072 0.84
Fasting glucose (mmol/L) Fasting glucose
Pre 5.4 (4.9 to 5.6) 5.3 (5.0 to 5.6)
Post 5.5 (5.3 to 6.3) 5.0 (4.8 to 5.7)
Diff 0.2 (− 0.1 to 0.4) 0.058 −0.2 (− 0.4 to − 0.03) 0.009 0.71
HbA1c (%) HbA1c
Pre 5.8 (5.6 to 6.1) 5.6 (5.4 to 5.8)
Post 5.8 (5.6 to 6.1) 5.4 (5.2 to 5.6)
Diff 0.0 (− 0.1 to 0.1) 0.87 −0.05 (− 0.2 to 0.0) 0.057 0.11
IL-8 (mmol/L) IL-8
Pre 9.0 (7.7 to 10.3) 7.5 (7.2 to 8.4)
Post 9.2 (6.9 to 11.1) 7.8 (7.2 to 8.9)
Diff 0.0 (− 1.5 to 1.2) 0.80 0.2 (− 1.0 to 1.5) 0.79 0.41
MCP-1 (pg/mL) MCP-1
Pre 42.2 (10.3 to 59.4) 51.7 (40.9 to 70.2)
Post 41.3 (11.1 to 60.2) 52.8 (45.1 to 93.7)
Diff 0.0 (− 5.4 to 1.7) 0.55 1.9 (0.2 to 17.5) 0.014 0.95
RANTES (pg/mL) RANTES
Pre 9206 (8172 to 9833) 8800 (8370 to 9761)
Post 8918 (8046 to 9942) 9164 (8651 to 10027)
Diff −161 (− 730 to 677) 0.81 19.09 (− 633 to 1105) 0.41 0.003
TNFa (pg/mL) TNFan = 19
Pre 10.1 (7.8 to 13.3) 6.5 (6.1 to 10.9)
Post 9.9 (6.5 to 13.9) 8.0 (5.8 to 11.4)
Diff 0.9 (− 2.8 to 2.9) 0.74 −0.4 (− 1.5 to 3.9) 0.66 0.26
RANTES; CCL-5/RANTES (regulated on activation, normal T-cell expressed and secreted); Diff, median difference between baseline and follow up serum measurements;
IQR, interquartile range; mmol/L, millimol/liter; pg/mL, picomol/liter. ∗The within group difference from baseline to study end. #The between group differences for 1
(difference from baseline to study end).
test word (p < 0.001) and color (p = 0.044) (Table 4 and
Supplementary Figures S5–S7).
Overall, findings using parametric analyses differed only
marginally from the non-parametric findings reported above
(Supplementary Tables S1, S2).
The compliance was good. More than 85% of the
participants returned at least 90% of the empty blister
packages. The anthocyanins were well tolerated, and
none of the participants withdrew due to adverse effects.
Blood tests taken for safety reasons were all within a
clinically acceptable range. Increased bleeding tendency
was not observed.
DISCUSSION
In this pilot study anthocyanin supplementation was well
tolerated, without any AE, and the compliance was good.
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TABLE 3 | Changes from baseline to 16 weeks follow-up in plasma anthocyanin metabolites, for participants with supplementation (active) and for control participants.
Active (n = 27) Control (n = 20) Active vs.
control
nmol/L Median (IQR) p∗ Median (IQR) p∗ p#
Methylpyrogallol-O-sulfate
Pre 33.1 (17.5 to 52.5) 26.2 (10.2 to 67.6)
Post 45.5 (24.1 to 104.2) 20.6 (7 to 65.3)
Diff 15.6 (− 3.3 to 70.7) 0.068 −1.7 (− 23.8 to 13.0) 0.85 0.14
Pyrogallol-2-O-sulfate
Pre 36.4 (17.2 to 110.5) 58.4 (20.4 to 102.4)
Post 63.8 (41.5 to 199.1) 35.2 (21.2 to 93.1)
Diff 17.5 (− 8.3 to 106.4) 0.001 −12.3 (− 82.4 to 32.1) 0.41 0.89
Protocatechuic acid-3-O-sulfate
Pre 3.5 (0.3 to 11.1) 5.4 (1.6 to 10.1)
Post 11.0 (5.5 to 26.5) 6.5 (0.3 to 16.4)
Diff 6.2 (0.0 to 21.6) 0.007 0.8 (− 6.3 to 10.1) 0.81 0.071
1-Methylpyrogallol-O-sulfate
Pre 44.7 (29.2 to 77.3) 60.8 (34.8 to 123)
Post 52.7 (33.6 to 97.2) 71.8 (30.3 to 106)
Diff 12.8 (− 19.6 to 32.7) 0.14 10.4 (− 27.8 to 65.5) 0.60 0.70
4-Methylgallic-3-O-sulfate
Pre 14.0 (5.6 to 23.8) 13.1 (8.5 to 28.7)
Post 12.8 (7.1 to 24.6) 12.3 (7.3 to 21.1)
Diff 1.6 (− 7.8 to 14.3) 0.65 −5.5 (− 15.6 to 12.0) 0.35 0.25
4-Hydroxybenzoic acid-O-sulfate
Pre 2027 (1211 to 4284) 2664 (1455 to 3764)
Post 1704 (772 to 3597) 1723 (420 to 4354)
Diff −97 (− 1039 to 234) 0.14 −924 (− 2691 to 1046) 0.26 0.67
4-Hydroxyhippuric acid
Pre 164 (93 to 272) 145 (117 to 275)
Post 123 (94 to 283) 111 (91 to 163)
Diff 6 (− 84 to 44) 0.84 −33 (− 236 to 33) 0.079 0.21
Protocatechuic acid
Pre 57.5 (22.0 to 106.8) 66.6 (35.5 to 127)
Post 51.3 (29.4 to 114.2) 48.7 (5.0 to 76.9)
Diff 1.6 (− 49.7 to 51.3) 0.75 −22.0 (− 85.2 to 17.2) 0.049 0.057
Pyrogallol-1-O-sulfate
Pre 25.6 (15.3 to 61.2) 55.1 (25.3 to 106.5)
Post 52.9 (25.5 to 97.6) 63.8 (41.4 to 94.4)
Diff 18.8 (1.5 to 68.4) 0.006 −2.9 (− 36.3 to 45.7) 0.85 0.093
3,4-Dihydroxyphenylacetic acid
Pre 174 (100 to 237) 122 (85 to 197)
Post 106 (84 to 213) 98 (75 to 163)
Diff −26 (− 135 to 69) 0.20 −33 (− 67 to 2) 0.044 0.97
Catechol-O-sulfate
Pre 5518 (2718 to 8056) 5986 (4284 to 7527)
Post 4640 (3183 to 7843) 4690 (3576 to 5627)
Diff 367 (− 2569 to 1608) 0.61 −937 (− 3502 to 2010) 0.25 0.67
Vanillic acid-4-O-sulfate
Pre 30.6 (9.5 to 47.8) 24.6 (9.6 to 39.6)
Post 26.2 (9.8 to 42.3) 22.6 (7.9 to 34.7)
Diff −6.5 (− 27.6 to 10.8) 0.20 −5.2 (− 15.0 to 23.8) 1.0 0.41
3-Hydroxyhippuric acid
Pre 709 (191 to 3060) 451 (269 to 1343)
(Continued)
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TABLE 3 | Continued
Active (n = 27) Control (n = 20) Active vs.
control
nmol/L Median (IQR) p∗ Median (IQR) p∗ p#
Post 339 (63 to 1233) 162 (35 to 599)
Diff −503 (− 1246 to − 55) 0.002 −183 (− 1117 to 196) 0.10 0.28
p-Coumaric acid-4-O-β-D-glucuronide
Pre 0.29 (0.00 to 0.52) 0.23 (0.00 to 0.46)
Post 0.21 (0.11 to 0.41) 0.17 (0.00 to 0.30)
Diff −0.07 (− 0.26 to 0.24) 0.92 0.01 (− 0.20 to 0.20) 0.94 0.84
Isovanillic acid-3-O-sulfate
Pre 2.3 (0.0 to 8.3) 5.5 (0.0 to 19.1)
Post 2.8 (0.0 to 11.3) 5.7 (0.3 to 14.4)
Diff 0.0 (− 3.5 to 11.3) 0.90 −1.1 (− 10.6 to 3.6) 0.50 0.48
Catechol-O-1-glucuronide
Pre 1.7 (0.0 to 9.2) 2.2 (0.1 to 8.0?)
Post 4.6 (1.6 to 14.2) 1.1 (0.1 to 6.6)
Diff 1.5 (− 1.5 to 8.8) 0.075 0.1 (− 2.2 to 1.7) 0.97 0.14
Ferulic acid-4-O-β-D-glucuronide
Pre 4.3 (0.4 to 33.4) 7.7 (1.0 to 19.4)
Post 19.4 (2.6 to 59.3) 5.8 (1.1 to 21.5)
Diff 5.5 (0.2 to 31.4) 0.013 −0.3 (− 5.9 to 15.4) 0.98 0.064
Hippuric acid
Pre 17680 (9444 to 55008) 24075 (11958 to 39646)
Post 15225 (8654 to 40673) 12211 (11086 to 28936)
Diff −3572 (− 18398 to 1041) 0.068 −2788 (− 15907 to 4975) 0.33 0.68
4-Methylcatechol-O-sulfate
Pre 1630 (815 to 3580) 1209 (753 to 1889)
Post 1228 (691 to 2722) 997 (647 to 1899)
Diff −182 (− 1087 to 733) 0.47 −221 (− 617 to 255) 0.28 0.95
4-Hydroxybenzaldehyde
Pre 72.6 (40.3 to 130) 81.2 (58.4 to 105)
Post 53.5 (48.9 to 93.3) 48.7 (39.5 to 75.5)
Diff −24.8 (− 56.1 to 6.5) 0.029 −34.3 (− 52.8 to − 6.8) 0.019 0.78
Ferulic acid-4-O-sulfate
Pre 2.3 (0.5 to 7.0) 4.0 (0.0 to 12.3)
Post 1.9 (0.8 to 23.8) 6.1 (1.6 to 9.7)
Diff 0.5 (− 2.9 to 21.1) 0.20 1.1 (− 7.7 to 9.1) 0.55 0.69
Dihydroisoferulic acid-3-O-sulfate
Pre 7.2 (0.0 to 17.5) 4.9 (0.0 to 14.1)
Post 9.2 (2.1 to 23.7) 7.6 (1.0 to 19.4)
Diff 1.0 (− 7.5 to 8.6) 0.47 0.9 (− 6.9 to 13.0) 0.69 0.94
Isoferulic acid-3-O-sulfate
Pre 1.1 (0.3 to 2.3) 0.8 (0.4 to 5.7)
Post 4.5 (0.4 to 13.7) 1.5 (0.3 to 8.6)
Diff 0.6 (− 1.7 to 10.2) 0.25 0.4 (− 1.6 to 2.4) 0.55 0.67
Dihydroisoferulic acid-3-O-β-D-glucuronide
Pre 19.1 (7.2 to 45.7) 25.8 (2.5 to 82.4)
Post 20.7 (8.1 to 60.8) 16.1 (5.4 to 43.4)
Diff 1.2 (− 15.4 to 34.5) 0.47 −4.9 (− 70.9 to 27.7) 0.55 0.31
Isoferulic acid-3-O-β-D-glucuronide
Pre 22.3 (5.2 to 67.5) 21.2 (1.8 to 54.6)
Post 27.3 (8.5 to 136.4) 21.3 (5.7 to 58.6)
Diff 24.4 (− 18.0 to 96.2) 0.044 2.7 (− 10.1 to 36.8) 0.55 0.21
(Continued)
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TABLE 3 | Continued
Active (n = 27) Control (n = 20) Active vs.
control
nmol/L Median (IQR) p∗ Median (IQR) p∗ p#
Dihydroferulic acid-4-O-sulfate
Pre 3.7 (1.2 to 8.3) 1.9 (0.2 to 3.6)
Post 1.6 (0.9 to 5.1) 2.7 (1.4 to 5.2)
Diff −1.5 (− 3.1 to − 0.3) 0.006 0.8 (− 0.9 to 2.9) 0.31 0.010
3-(3-hydroxyphenyl)propanoic acid
Pre 805 (44 to 2377) 350 (14 to 1479)
Post 470 (72 to 4306) 414 (112 to 1624)
Diff 29 (− 495 to 831) 0.43 36 (− 917 to 345) 0.74 0.76
m-Coumaric acid
Pre 111 (35 to 146) 84 (63 to 110)
Post 55 (38 to 78) 58 (53 to 85)
Diff −62 (− 82 to 16) 0.014 −28 (− 58 to 2) 0.093 0.33
o-Coumaric acid
Pre 218 (81 to 356) 125 (81 to 234)
Post 87 (47 to 158) 81 (50 to 162)
Diff −116 (− 230 to − 35) <0.001 −36 (− 111 to − 1) 0.006 0.019
Diff, median difference between baseline and follow up plasma measurements; IQR, interquartile range; nmol/L = nanomol/liter. ∗The within group difference from baseline
to study end. #The between group differences for 1 (difference from baseline to study end).
This indicates that larger RCTs might be feasible, to confirm
exploratory results in the current pilot study.
Our findings are somewhat inconclusive. While some
cognitive improvements were observed in the AG, there were
no significant changes in serum levels of some risk factors
for dementia; i.e., fasting glucose, HbA1c or pro-inflammatory
cytokines. There was a non-significant decrease in serum levels
of RANTES in the AG and a non-significant increase in the NC
during the study period. However, the between-group difference
in 1 serum levels of RANTES was statistically significant.
Furthermore, we observed a significant increase in serum
levels of total cholesterol and triglycerides in AG. The lipid profile
of the NC group did not change significantly, and since we have
no information about statin use or use of other lipid lowering
medications in the NC group, the observed difference should be
interpreted cautiously.
Previous studies using Medox R© have shown a statistically
significant increase in HDL-cholesterol (Qin et al., 2009; Zhu
et al., 2011; Hassellund et al., 2013) and a decrease in
LDL-cholesterol (Qin et al., 2009; Zhu et al., 2011). This is of
clinical interest, as higher HDL-cholesterol is associated with
lower cardiovascular risk (Barter et al., 2007), while high levels of
total cholesterol, triglycerides and LDL are associated with higher
cardiovascular risk (Stone et al., 2014).
The differences in the findings between our study and these
previous studies might be due to differences in participants, as
well as in anthocyanin supplementation dose and duration, or
other factors. Furthermore, other studies included dyslipidemic
and hypercholesterolemic participants not using statins or any
other lipid lowering treatment (Qin et al., 2009; Zhu et al., 2011),
whereas in our study, the median cholesterol at baseline in the
intervention group was 4.0 mmol/l, in addition 70% were taking
statins or other lipid lowering medication.
Regarding the inflammation markers, RANTES promotes
activation and migration of leukocytes and mediates
neuroinflammation and brain microvascular dysfunction
(Appay and Rowland-Jones, 2001; Dénes et al., 2010; Yilmaz and
Granger, 2010). There was a significant between-group difference
for 1RANTES, although anthocyanin supplementation did not
significantly reduce RANTES in the AG. Still, our results are
consistent with similar findings in a randomized, double-blind
trial in hypercholesterolemic individuals consuming purified
anthocyanins for 24 weeks (Song et al., 2014), and in a
parallel-designed, placebo-controlled trial (Karlsen et al., 2007).
Other studies did not report a reduction of pro-inflammatory
mediators after anthocyanin supplementation (Hassellund et al.,
2013; Kent et al., 2015). Therefore, the anti-inflammatory effect
of anthocyanins and the potential to reduce neuroinflammation
and brain microvascular dysfunction associated with cognitive
decline in adults at risk of dementia (Grammas, 2011) should be
studied in larger randomized studies.
The beneficial effect of anthocyanins might possibly be
due to their degradation products and metabolites (Feliciano
et al., 2016) as absorption of intact anthocyanins is reported
to be low (Zhong et al., 2017). Rodriguez-Mateos et al.
quantified metabolites in plasma after blueberry consumption,
and showed that anthocyanin-derived metabolites correlated
with in vivo effects (Rodriguez-Mateos et al., 2013, 2019).
Furthermore, circulating anthocyanin metabolites were shown
to improve vascular function when injected in an in vivo
model of vascular function, and cardiovascular benefits after
consumption of anthocyanins were linked with anthocyanin
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TABLE 4 | Changes from baseline to 16 weeks follow-up in cognitive variables, for
participants with supplementation (active).
Active (n = 27)
Median (IQR) p∗
CERAD (points) Learning
Pre 20 (16 to 22)
Post 21 (17 to 25)
Diff 2 (− 1 to 3) 0.016
Recall
Pre 6 (4 to 8)
Post 7 (5 to 9)
Diff 1 (0 to 2) <0.001
Recognition
Pre 20 (16 to 20)
Post 20 (19 to 20)
Diff 0 (0 to 1) 0.047
TMT A (sec)
Pre 32 (21 to 53)
Post 34 (23 to 39)
Diff −2 (− 6 to 2) 0.081
TMT Bn = 19 (sec)
Pre 85.50 (62.25 to 118)
Post 69.50 (56 to 100.75)
Diff −2.0 (− 19.75 to 2.25) 0.16
STROOP (score) Word
Pre 87 (72 to 67)
Post 87 (80 to 103)
Diff 6 (1 to 10) <0.001
Color
Pre 61 (52 to 67)
Post 62 (54 to 69)
Diff 2 (− 1 to 6) 0.044
Word-color
Pre 34 (29 to 41)
Post 34 (28 to 41)
Diff 0 (− 3 to 5) 0.67
TMT, Trail Making Test; Diff, median difference between baseline and follow up
results in cognitive tests; IQR, interquartile range. ∗The within group difference from
baseline to study end.
metabolites as mediators of change in cellular gene programs
(Rodriguez-Mateos et al., 2019).
In our study, we were able to measure a total of 29 anthocyanin
metabolites. The results were conflicting, as we found various
anthocyanin metabolites to be both significantly increasing and
decreasing in the AG. In the NC group as well, we found
significant changes. This is in line with findings in another
study reporting an increase of some metabolites, and a decrease
in others after ingestion of anthocyanins over time (Feliciano
et al., 2016). A possible explanation for our results could be high
inter-individual variability and the influence of the background
diet on the concentration of these compounds in blood, as some
of these metabolites could arise from the consumption of other
anthocyanin-rich foods such as berries and red wine or other
food components in the diet. It is also possible that the results
could be related to the handling and analysis of the blood samples.
As far as we know, the presence of anthocyanin metabolites in
plasma after Medox R© use is reported in only one other clinical
study, where 8 out of 17 anthocyanin metabolites were found to
be significantly increased. However, this was analyzed in blood
samples collected 1–3 h after ingestion of the morning dose of
anthocyanins (320 mg), and not after daily consumption and an
overnight fast (Hassellund et al., 2013).
The improvement on several cognitive tests should be
interpreted cautiously due to potential learning effects related
to the relatively short test–retest interval, and the lack of
a comparison group. Nonetheless, our results are in line
with previous smaller studies involving participants with MCI,
reporting improved cognition after ingestion of anthocyanins
(Krikorian et al., 2010a,b). Our results are also in line with
the results of a randomized, double-blinded, placebo-controlled
study reporting improved episodic memory after 3 months of
anthocyanin supplementation (Whyte et al., 2018).
Intake of anthocyanin capsules in the dosage of 320 mg/day
appears to be well tolerated and safe. None of the safety
blood tests were found to be out of a clinically acceptable
range or necessitating medical follow-up after study-end. This
is consistent with previous studies (Karlsen et al., 2007;
Qin et al., 2009).
The major limitations of this pilot study are the
non-randomized open-label design, the small sample size,
and the relatively short intervention period. Although all the
participants were told not to change their lifestyle during the
intervention period, we have no data on this. Further we had
no detailed dietary assessment, and thus we cannot exclude the
possibility of differences in the background diet between the
groups before or during the study. However, the participants
were instructed to maintain their dietary and lifestyle habits
during the study period, and to take the capsules 30 min before or
120 min after meals, as concomitant ingestion of certain types of
food may counteract the effect of flavonoids (Lorenz et al., 2007).
The NC were recruited separately and differed from the
participants by being a healthy group that did not receive
any intervention, and did not perform cognitive testing. Thus
power calculations for further studies might be compromised.
However, we provide descriptive statistics including variance
measurements which may be helpful in planning sample size
in later studies.
An important strength of our study is the well characterized
combination of nutraceuticals used, which facilitates comparison
with other studies regarding both source of anthocyanins and
dosage. Of note, this is, to our knowledge, the first study on
cognitive function in adults with increased risk of dementia
where Medox R© is being used as the source of anthocyanin.
Thus our study might also facilitate investigation of the effect
of different proprietary blueberry formulatons, shown by Whyte
et al. to be of importance (Whyte et al., 2018).
All things considered, adequately powered, randomized
studies are warranted to better understand how anthocyanins
and their metabolites may affect relevant mechanisms, including
their possible protective role in epigenetic modifications
that potentially benefit the aging brain and reduce the
risk for dementia.
Frontiers in Genetics | www.frontiersin.org 9 June 2019 | Volume 10 | Article 536
Bergland et al. Anthocyanin Pilot Study
ETHICS STATEMENT
All participants provided written informed consent, and the
study has been approved by the Regional Ethics Committee
(Approval 2014/1966). The study has been registered at
ClinicalTrials.gov (NCT02409446).
AUTHOR CONTRIBUTIONS
DA, HS, AB, and AL planned and designed the study. AB
conducted the study and collected the data. RB performed
the serum analyses. MT and AR-M performed the plasma
analyses. AB and ID conducted the statistical analyses.
All authors wrote the manuscript and critically reviewed
the manuscript.
FUNDING
This study was financed by a grant from Sandnes Sparebank,
Sandnes, Norway and the Norwegian Health Association,
grant number 7330. Medpalett, Sandnes, Norway contributed
to the study by producing Medox R© free of charge.
Medpalett had no influence on the design or conduction
of the study, the analyses and interpretation of data, or
regarding the decision to publish the findings. This paper
represents independent research partly funded by the National
Institute for Health Research (NIHR) Biomedical Research
Centre at South London and Maudsley NHS Foundation
Trust and King’s College London. The views expressed
are those of the author and not necessarily those of
the NHS, the NIHR or the Department of Health and
Social Care.
ACKNOWLEDGMENTS
We would like to thank the research nurses Reidun Sikveland
Meling and Jorunn Margrete Nilsen for their contribution in
the conduction of the study. We also thank Hellen Svalestad for
her contribution to participant recruitment from the cardiology
department, and Bjarne Hervik for his contribution in recruiting
healthy normal controls.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fgene.
2019.00536/full#supplementary-material
FIGURE S1 | Changes from baseline to 16 weeks follow-up in serum lipids, for
participants with anthocyanin supplementation. mmol/L, millimole/liter.
FIGURE S2 | Changes from baseline to 16 weeks follow-up in serum fasting
glucose and HbA1c, for participants with anthocyanin supplementation. HbA1a,
glycosylated hemoglobin; mmol/L, millimole/liter.
FIGURE S3 | Changes from baseline to 16 weeks follow-up in serum cytokines,
for participants with anthocyanin supplementation. RANTES;CCL-5/RANTES
(regulated on activation, normal T-cell expressed and secreted). pg/mL,
picomolar/milliliter.
FIGURE S4 | Changes from baseline to 16 weeks follow-up in plasma
anthocyanin metabolites, for participants with and without anthocyanin
supplementation. Measurement unit: nmol/L, nanomolar/liter, except for hippuric
acid (nmol/10L) and coumaric acid-4-O-β-D-glucuronide (nmol/0.033L).
FIGURE S5 | Changes from baseline to 16 weeks follow-up in CERAD.
FIGURE S6 | Changes from baseline to 16 weeks follow-up in Trail Making Test
(TMT). Sec, seconds.
FIGURE S7 | Changes from baseline to 16 weeks follow-up in Stroop test.
TABLE S1 | Changes from baseline to 16 weeks follow-up in serum variables, for
participants with supplementation (active) and for control participants. x̄, mean;
SD, standard deviation; ∗The within group difference from baseline to study end
tested with paired-samples t-test. $ independent samples t-test for the between
group differences for 1 (difference from baseline to study end). #With Welch
correction for heteroscedasticity. RANTES;CCL-5/RANTES (regulated on
activation, normal T-cell expressed and secreted). Diff, mean difference between
baseline and follow up results in serum measurements.
TABLE S2 | Changes from baseline to 16 weeks follow-up in cognitive variables,
for participants with supplementation (active). x̄, mean; SD, standard deviation;
TMT, Trail Making Test; Diff, mean difference between baseline and follow up
results in cognitive tests. ∗The within group difference from baseline to study end
tested with paired-samples t-test.
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Table S2 Changes from baseline to 16 weeks follow-up in cognitive variables, for participants 
with supplementation (active). 
 
            Active (n = 27) 




          Pre 19.4 (4.6, 8 to 27) 
          Post 20.8 (5.4, 8 to 29) 




         Pre 5.8 (2.2, 1 to 9) 
         Post 6.9 (2.6, 1 to 10) 




         Pre 18.7 (1.7, 14 to 20) 
         Post 19.2 (1.6, 13 to 20) 
         Diff. 0.5 (1.4, -4 to 4) 0.091 
TMT A   
         Pre 35.5 (12.5, 15 to 66) 
         Post 32.3 (12.2, 13 to 64) 
         Diff. -3.2 (8.4, -26 to 10) 0.059 
TMT B   
         Pre 96.9 (47.2, 48 to 226) 
         Post 91.0 (63.7, 47 to 321) 




         Pre 83.4 (17.16, 48 to 115) 
         Post 88.8 (17.9, 49 to 119) 




         Pre 58.9 (12.9, 26 to 83) 
         Post 61.4 (12.9, 38 to 88) 




         Pre 34.0 (11, 11 to 56) 
         Post 34.2 (12, 14 to 60) 
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2014/1966  Effekten av Medox på blodlipider, inflammasjon og oksidativt stress 
 Helse Stavanger HFForskningsansvarlig:
 Dag ÅrslandProsjektleder:
Vi viser til søknad om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Søknaden ble behandlet av
Regional komité for medisinsk og helsefaglig forskningsetikk (REK sør-øst) i møtet 26.11.2014. 
Vurderingen er gjort med hjemmel i helseforskningsloven (hfl.) § 10, jf. forskningsetikkloven § 4.
Prosjektomtale
Teste hypotesen; kardiovaskulære fysiologiske mekanismer, og markører for inflammasjon og oksidasjon i
blod, endrer seg i gunstig retning etter behandling med antocyaner (kosttilskudd) hos personer med økt
risiko for demens, dvs med koronar hjertesykdom og/eller mild kognitiv svikt. Forskningen; i 2 faser: Fase 1
(Åpen pilotstudie) Inkluderer 30 pasienter som blir gitt Antocyaner i 16 uker. Blodprøve + kognitiv test +
fysiologiske tester(Kondisjonstest, Flow-mediert endotelfunksjon, koronar gjennomstrømningsreserve og
kontinuerlig rytmeovervåkning av hjertet i 24 timer) v/ baseline og etter 16 uker Fase 2: Randomisert
placebo-kontrollert paralellgruppestudie. 150 pasienter-som ovenfor. Endepunkt; blodprøver som har vist
vist effekt av antocyaner i fase 1. Blodprøver + kognitive tester tas v/baseline og etter 6 mnd. Subgruppe-
Kondisjonstet, Undersøke blodåre på underarmen, gjort hjertefunksjonsvurdering via ultralyd av hjertet og
kontinuerlig rytmeovervåkning av hjertet i 24 timer.
Vurdering
I denne studien skal 30 personer med økt risiko for demens inkluderes i en åpen pilotstudie der de får
antocyaner i 16 uker og skal evalueres for gunstig effekt på inflammasjon og oksidasjon ved hjelp av en
rekke tester. I fase 2 skal 150 pasienter randomiseres til placebo eller antocyan. Endepunkt er blodprøver
som har vist effekt i fase 1.
Komiteen er ikke innstilt på å godkjenne fase 2 av studien før fase 1 er gjennomført. Når fase 1 er
gjennomført ber komiteen om en redegjørelse for resultatene, før komiteen vurderer fase 2.
Komiteen har ingen innvendinger mot at fase 1 studien gjennomføres som beskrevet i søknad og protokoll.
Kosttilskuddet er allerede godkjent og anbefalt brukt hos pasientgruppen. Det er ingen kjente bivirkninger.
Deltagelse innebærer en rekke tester, men ingen er forbundet med risiko.
Det opplyses om at blodprøver skal lagres i en generell biobank for forskning om aldersrelaterte
hjernesykdommer (SESAM-biobanken), REK-referanse 2014/328. Blodprøvene skal sendes til Karolinsk
Institutt, Sverige, for analyse. Komiteen ber om at deltagerne får informasjonsskriv og samtykkeerklæring
for avgivelse av materiale til den generelle forskningsbiobanken, i tillegg til informasjonsskriv og
samtykkeerklæring for denne konkrete studien.  Komiteen mener at deltagerne bør gis mulighet til å
reservere seg mot at materialet inngår i en generell forskningsbiobank, men at de likevel kan delta i studien.
Komiteen setter følgende vilkår for godkjenning av fase 1:
-Deltagerne skal få informasjonsskriv/samtykkeerklæring for avgivelse av materiale til den generelle
forskningsbiobanken, i tillegg til informasjonsskriv og samtykkeerklæring for denne konkrete studien.
- Deltagerne skal gis mulighet til å reservere seg mot at materialet inngår i en generell forskningsbiobank,
men at de likevel kan delta i studien.
Vedtak
Med hjemmel i helseforskningsloven § 9 jf. 33 godkjenner komiteen at fase 1 av studien gjennomføres
under forutsetning av at ovennevnte vilkår oppfylles.
I tillegg til vilkår som fremgår av dette vedtaket, er godkjenningen gitt under forutsetning av at prosjektet
gjennomføres slik det er beskrevet i søknad og protokoll, og de bestemmelser som følger av
helseforskningsloven med forskrifter.
Med hjemmel i helseforskningsloven § 29 tillater komiteen at humant biologisk materiale utføres til
utlandet.
Tillatelsen gjelder til 20.11.2016. Av dokumentasjonshensyn skal opplysningene likevel bevares inntil
20.11.2021. Forskningsfilen skal oppbevares avidentifisert, dvs. atskilt i en nøkkel- og en opplysningsfil.
Opplysningene skal deretter slettes eller anonymiseres, senest innen et halvt år fra denne dato.
Forskningsprosjektets data skal oppbevares forsvarlig, se personopplysningsforskriften kapittel 2, og
Helsedirektoratets veileder for «Personvern og informasjonssikkerhet i forskningsprosjekter innenfor helse
og omsorgssektoren».
Dersom det skal gjøres vesentlige endringer i prosjektet i forhold til de opplysninger som er gitt i søknaden,
må prosjektleder sende endringsmelding til REK.
Prosjektet skal sende sluttmelding på eget skjema, senest et halvt år etter prosjektslutt.
Klageadgang
REKs vedtak kan påklages, jf. forvaltningslovens § 28 flg. Klagen sendes til REK sør-øst D. Klagefristen er
tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av REK sør-øst D, sendes klagen videre
til Den nasjonale forskningsetiske komité for medisin og helsefag for endelig vurdering.
Vi ber om at alle henvendelser sendes inn på korrekt skjema via vår saksportal:
http://helseforskning.etikkom.no. Dersom det ikke finnes passende skjema kan henvendelsen rettes på e-post
til: post@helseforskning.etikkom.no.
Vennligst oppgi vårt referansenummer i korrespondansen.
Med vennlig hilsen
Finn Wisløff




Kopi til:stein.tore.nilsen@sus.no; Stavanger universitetssjukehus ved øverste administrative ledelse: 
post@helse-stavanger.no
10.2 Consent form for Anthocyanin group 
  





Bakgrunn og hensikt 
 
Forskere tilknyttet SESAM (Regionalt kompetansesenter for eldremedisin og samhandling) og 
kardiologisk avdeling ved Stavanger universitetssjukehus ønsker å finne ut om antocyaner, gitt i form 
av Medox® kapsler.har positive helseeffekter. 
 
Mer presist ønsker vi å undersøke om antocyaner kan påvirke mekanismer som vi tror bidrar til 
utviklingen av både hjerte-/kar-sykdom og hukommelsesproblemer. 
 
Virkestoffet i Medox kapsler er antocyaner, som er stoffer som finnes i mørke bær (som blåbær og 
solbær), frukt og flere andre plantevekster. De utgjør plantenes «immunforsvar». Disse stoffene har vist 
seg å ha antioksidative egenskaper, d.v.s. at de kan beskytte mot skadelige kjedereaksjoner i kroppens 
celler som potensielt ville kunne bidra til utvikling av karsykdom og hukommelsesproblemer.  
 
Resultatene fra ulike tidligere studier tyder også på at antocyaner reduserer kronisk inflammasjon, altså 
en indre betennelsestilstand i kroppen, som er knyttet til de aller fleste kroniske sykdommer. 
Betennelsesnivået øker med alderen og bidrar til at risikoen for å få flere sykdommer øker etter hvert 
som man blir eldre. Andre resultater tyder på at antocyaner kan bidra til å heve det «gode» kolesterolet 
på bekostning av det «dårlige». Påvirkning av disse disse faktorene i gunstig retning kan tenkes å 
redusere faren for å utvikle hukommelsesproblemer. 
 
 
Hva innebærer studien?   
 
Aktuelle studiedeltakere er personer over 50 år som har stabil koronar hjertesykdom. I tillegg vil vi 
inkludere personer som har begynnende hukommelsesproblemer. 
 
Praktisk gjennomføring 
Studiedeltakerne vil bli gitt Medox kapsler i 16 uker.  
 
De som skal delta i studien må si seg villig til å bli tatt blodprøver av, bli intervjuet og få utført generell 
medisinsk undersøkelse, , samt å gjennomgå enkle hukommelsestester.  
 
Undersøkelsene vil bli gjort  ved studiestart, så etter 16 uker. Ved begge tilfellene må deltakerne møte 
to  ganger. Først hos lege så hos sykepleier.Man får utlevert Medox kapsler som man skal ta  daglig, 2 
om morgenen og 2 om kvelden i 16 uker. Etter 8 uker vil deltakerne bli kontaktet av studieleder. Etter 
endt studie skal deltakerne levere  inn de tomme Medox-eskene.  
Forskerne vil deretter undersøke om det er forskjeller i målingene og testene mellom starttidspunkt og 
etter 16 uker med inntak av Medox.  
 
Medox er et norsk produkt, utviklet og produsert i Norge. Produsenten, BioLink, vil være involvert i 
prosjektet med å levere Medox kapsler, men prosjektet er planlagt og vil gjennomføres av forskere ved 






Mulige fordeler og ulemper 
 
Det vil ikke være økonomiske kostnader forbundet med deltakelse i studien. Eventuelle utgifter vil bli 
refundert.  
Medox er et naturprodukt og har ingen kjente potensielt farlige bivirkninger. Utover ubehag i 
forbindelse med blodprøver og undersøkelser er det derfor ingen risiko ved å delta. 
 
Hva skjer med prøvene og informasjonen om deg? Personvern 
 
Prøvene tatt av deg og informasjonen som registreres om deg (relevante helseopplysninger, prøvesvar, 
og resultat på undersøkelsene samt alder og kjønn) skal kun brukes som beskrevet i hensikten med 
studien. Alle opplysningene og prøvene vil bli behandlet uten navn og fødselsnummer og andre 
opplysninger som kan brukes for å identifisere deg. En kode knytter deg til dine opplysninger og prøver 
gjennom en navneliste. Det betyr at all informasjon om deg er avidentifisert. 
 
Det er kun autorisert personell knyttet til prosjektet som har adgang til navnelisten og som kan finne 
tilbake til deg.  




Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt samtykke 
til å delta i studien. Dette vil ikke få konsekvenser for din videre behandling. Dersom du ønsker å delta, 
undertegner du samtykkeerklæringen på siste side. Om du nå sier ja til å delta, kan du senere trekke 
tilbake ditt samtykke uten at det påvirker din øvrige behandling. Dersom du senere ønsker å trekke deg 
eller har spørsmål til studien, kan du kontakte;  
 
Overlege/forsker Anne Katrine Bergland  anhe@sus.no tlf 97430694 

























Blodprøvene som blir tatt vil bli lagret i en forskningsbiobank ved SUS (SESAM-biobanken). 
Hvis du sier ja til å delta i studien, gir du også samtykke til at det biologiske materialet og 
analyseresultater inngår i biobanken. Dag Årsland er ansvarshavende for 
forskningsbiobanken. Det biologiske materialet kan bare brukes etter godkjenning fra 
Regional komité for medisinsk og helsefaglig forskningsetikk (REK). 
 
Utlevering av materiale og opplysninger til andre 
Hvis du sier ja til å delta i studien, gir du også ditt samtykke til at prøver og avidentifiserte 
opplysninger utleveres til våre samarbeidspartnere ved Karolinska Institutet i Stockholm. 
 
Rett til innsyn og sletting av opplysninger om deg og sletting av prøver  
Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger som er 
registrert om deg. Du har videre rett til å få korrigert eventuelle feil i de opplysningene vi har 
registrert. Dersom du trekker deg fra studien, kan du kreve å få slettet innsamlede prøver og 
opplysninger, med mindre opplysningene allerede er inngått i analyser eller brukt i 
vitenskapelige publikasjoner.  
 
Økonomi og BioSynth Biolink? rolle 
Studien og biobanken er finansiert gjennom forskningsmidler fra Sandnes Sparebank. I tillegg 
bidrar produsenten av Medox ved å produsere Medox og placebo gratis til prosjektet. Utover 
dette har sponsor ingen innvirkning på planlegging og gjennomføring av studien 
 
Forsikring 
Deltakerne er forsikret gjnnom Pasientforsikringsloven 
 
Informasjon om utfallet av studien 
Deltakere har rett til å få informasjon om utfallet/resultatet av studien.  
 
Samtykke til deltakelse i studien 
 




(Signert av prosjektdeltaker, dato) 
 
 












(Signert, rolle i studien, dato) 
 
10.3 Consent form for normal controls 
 





Bakgrunn og hensikt 
 
Forskere tilknyttet SESAM (Regionalt kompetansesenter for eldremedisin og samhandling), og 
Kardiologisk avdeling ved Stavanger universitessykehus, ønsker nå å finne ut om Medox® kapsler har 
positive effekter på hjernen. I den forbindelse er flere pasienter inkludert i en studie hvor dette 
undersøkes, bl.a gjennom blodprøve analyser før og etter Medox-bruk. 
 
Forskningsgruppen ønsker nå å rekruttere personer til å delta i en kontrollgruppe. 
 
Hva innebærer studien?   
 
Aktuelle studiedeltakere er personer over 50 år som er villige til å avgi fastende blodprøver to ganger, 
med fire måneders mellomrom. 
 
Mulige fordeler og ulemper 
 
Det vil ikke være økonomiske kostnader forbundet med deltakelse i studien. Eventuelle utgifter vil bli 
refundert. Blodprøvetakingen vil kunne være forbundet med noe ubehag. Dog ikke utover det man 
forventer ved standard blodprøvetaking. 
  
Hva skjer med prøvene og informasjonen om deg? Personvern 
 
Prøvene tatt av deg og informasjonen som registreres om deg (relevante helseopplysninger, prøvesvar, 
samt alder og kjønn) skal kun brukes slik som beskrevet i hensikten med studien. Alle opplysningene og 
prøvene vil bli behandlet uten navn og fødselsnummer og andre opplysninger som kan brukes for å 
identifisere deg. En kode knytter deg til dine opplysninger og prøver gjennom en navneliste. Det betyr 
at all informasjon om deg er avidentifisert. 
 
Det er kun autorisert personell knyttet til prosjektet som har adgang til navnelisten og som kan finne 
tilbake til deg.  
Det vil ikke være mulig å identifisere deg i resultatene av studien når disse publiseres.  
 
 
Frivillig deltakelse  
Det er helt frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt 
samtykke til å delta i studien. Dette vil ikke få konsekvenser for deg. Dersom du ønsker å delta, 
undertegner du samtykkeerklæringen på siste side. Om du nå sier ja til å delta, kan du senere trekke 
tilbake ditt samtykke når som helst. Dersom du senere ønsker å trekke deg eller har spørsmål om 
studien, kan du kontakte  
 
Overlege/forsker Anne Katrine Bergland  anhe@sus.no tlf 97430694 












Blodprøvene som blir tatt vil bli lagret i en såkalt forskningsbiobank ved SUS (SESAM-biobanken). 
Hvis du sier ja til å delta i studien, gir du også samtykke til at det biologiske materialet og 
analyseresultater inngår i biobanken. Professor Dag Årsland er ansvarshavende for 
forskningsbiobanken. Det biologiske materialet kan bare brukes etter godkjenning fra Regional komité 
for medisinsk og helsefaglig forskningsetikk (REK). 
 
Utlevering av materiale og opplysninger til andre 
Hvis du sier ja til å delta i studien, gir du også ditt samtykke til at prøver og avidentifiserte opplysninger 
utleveres til våre samarbeidspartnere ved Karolinska Institutet i Stockholm. 
 
Rett til innsyn og sletting av opplysninger om deg og sletting av prøver  
Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger som er registrert om 
deg. Du har videre rett til å få korrigert eventuelle feil i de opplysningene vi har registrert. Dersom du 
trekker deg fra studien, kan du kreve å få slettet innsamlede prøver og opplysninger, med mindre 
opplysningene allerede er inngått i analyser eller brukt i vitenskapelige publikasjoner.  
 
Forsikring 
Deltakerne er forsikret gjennom Pasientforsikringsloven 
 
Informasjon om utfallet av studien 
Deltakere har rett til å få informasjon om utfallet/resultatet av studien.  
 
Samtykke til deltakelse i studien 
 




(Signert av prosjektdeltaker, dato) 
 
 


















Paper II, Page 1121; Corrected “PLS-DA” to “Partial least squares discriminant 
analysis (PLS-DA)”. 
Paper II, Page 1122, Table 1; Incorrect number for VOSP T-score Mean (SD) for 
Controls. Corrected to 52.9. 
Page 7 Incorrect words: “was found for the cytokine CCL-5/“regulated on activation, 
normal T-cell expressed and secreted” (RANTES). – corrected to “was found for 
monocyte chemoattractant protein (MCP-1) and fasting glucose.” 
Page 10 Missing word: “Vascular risk and dementia progression” – corrected to 
“Vascular risk factors and dementia progression” 
Page 34 Missing word: “Vascular risk and dementia progression” – corrected to 
“Vascular risk factors and dementia progression” 
Page 35 Missing word: “progression due AD” -corrected to “progression due to AD” 
Page 43 Incorrect numbers: Table 2 “CAD 8” – corrected to “CAD: 19” 
Page 43 Incorrect numbers: Table 2 “MCI: 19” – corrected to “MCI: 8”  
Page 60 Misspelling: “finding” – corrected to “findings“ 
Page 63 Incorrect words: “difference was for ΔRANTES (difference from baseline to 
study end) which decreased in the supplementation group and increased in the NC 
group (p=0.003).” – corrected to “difference were for ΔMCP-1 (difference from 
baseline to study end) (p=0.011) and Δfasting glucose (p=0.003).” 
Page 80 Missing word: “analysis showed significant differences.” – corrected to 
“analysis showed no significant differences.” 
Page 85 Incorrect words: “was with respect to the within-group difference of 
RANTES (difference from baseline to study end), which decreased non-significantly 
in the anthocyanin group and increased non-significantly in the normal control 
group.”– corrected to “was with respect to the within-group difference of MCP-1 and 
fasting glucose (difference from baseline to study end).” 
200 
 
Page 100 Incorrect reference: “Evans, R.M., et al., Serum cholesterol, APOE 
genotype, and the risk of Alzheimer's disease: a population-based study of African 
Americans. Neurology, 2000. 54(1): p. 240-2.” - corrected to “Evans, R.M., et al., 
Cholesterol and APOE genotype interact to influence Alzheimer disease progression. 
Neurology, 2004. 62(10): p. 1869-71.” 
Paper III, Page 5 Incorrect number: Table 2 Fasting glucose Active vs. control p# = 
0.71 Should read p# = 0.003 
Paper III, Page 5 Incorrect number: Table 2 HbA1c Active vs. control p# = 0.11 
Should read p# = 0.26 
Paper III, Page 5 Incorrect number: Table 2 IL-8 Active vs. control p# = 0.41  
Should read p# = 0.71 
Paper III, Page 5 Incorrect number: Table 2 MCP-1 Active vs. control p# = 0.0.95 
Should read p# = 0.011 
Paper III, Page 5 Incorrect number: Table 2 RANTES Active vs. control p# = 0.0.003 
Should read p# = 0.41 
Paper III, Page 5 Incorrect number: Table 2 TNFa Active vs. control p# = 0.26  
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